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Abstract: 
Joseph Della Rocca: Hybrid Nanoparticles for Anticancer Drug Delivery 
(Under the Direction of Wenbin Lin) 
 
 Nanoparticle-based anticancer has the potential to improve cancer therapy as they 
generally show greater efficacy with less toxicity than their small molecules counterparts. In 
this work, the synthesis, characterization, in vitro, and in vivo evaluation of nanoparticle 
platforms to deliver platinum anticancer drugs are discussed. 
 First, cisplatin-containing co-condensed silica nanoparticles were developed. These 
nanoparticles could deliver up to 30 wt% cisplatin and could be targeted to cancer cells by 
the surface attachment of appropriate ligands. The targeted nanoparticles had comparable 
efficacy to cisplatin in vitro. A new nanoparticle platform, known as polysilsesquioxanes 
(PSQ) was developed to deliver the platinum anticancer drugs cisplatin and oxaliplatin. 
These nanoparticles have remarkably high drug loading, up to 47 wt% oxaliplatin and 42 
wt% cisplatin, respectively, and can selectively release their cargos in the tumor 
environment. Both PSQ nanoparticles were functionalized with a polyethylene glycol (PEG) 
shell. In vivo evaluations against multiple xenograft models of pancreatic or lung cancers 
demonstrated that PSQ nanoparticles had comparable or better efficacy than oxaliplatin or 
cisplatin. Further development of all three nanoparticle platforms is ongoing to fully realize 
their clinical potential.  
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Chapter 1: 
Hybrid Nanoparticles for Anticancer Drug Delivery 
1.1 Introduction 
Cancer remains one of the deadliest diseases known to man, causing significant 
mortality and morbidity and costing hundreds of billions of dollars in healthcare expenses in 
the United States annually.  Despite remarkable advances in our knowledge of the 
fundamental biology of cancer and the billions of dollars spent on drug research and 
development, there has not been a significant increase in overall patient survival for many 
types of cancer. A major reason for this dilemma is the lack of effective chemotherapeutic 
options. Over the past thirty years, the rate of new drug approvals has remained relatively 
constant (20-30 drugs annually). Most new approvals are reformulations, new applications, 
or new combinations of previously approved agents.1  The treatment options for many 
cancers have remained nearly unchanged as a result of the lack of new drug approvals. 
Pharmaceutical development is limited by a number of factors including high research and 
development costs and regulatory barriers, but the lack of effective drug delivery vectors 
remains a major bottleneck.  Many drug candidates identified through high throughput 
screenings do not possess sufficient solubility to be bioavailable,2 and the biologically-
derived agents (e.g., peptides, proteins, and siRNA) are degraded readily by endogenous 
enzymes in circulation. The currently approved agents, mostly small molecules, are limited 
by their nonspecific biodistribution, leading to dose-limiting side effects.  There exists an 
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acute need to identify a method to make small molecule drugs more bioavailable, protect 
biologics from premature degradation, and increase tumor uptake of the agent while 
minimizing nonspecific uptake.  
Nanoparticle-based chemotherapeutics are an emerging class of drug delivery 
systems which have the potential to revolutionize cancer chemotherapy.  Broadly speaking, a 
nanoparticle- based chemotherapeutic (nanotherapeutic) consists of a therapeutic embedded 
within or attached to a nanoparticle matrix. A variety of nanocarriers have been developed to 
deliver a wide range of cancer chemotherapeutics.3 Nanoparticles possess many advantages 
over conventional therapeutics such as extended systemic circulation times, increased tumor 
uptake due to the enhanced permeability and retention (EPR) effect, and targeted delivery to 
specific tissues with surface-conjugated ligands. Due to their size, nanotherapuetics cannot 
penetrate normal vasculatures and capillaries, leading to a lower nanoparticle dose to normal 
tissues such as skin, muscle, lungs, hearts and kidneys compared to small molecules. The 
clearance of nanotherapuetics generally occurs through the mononuclear phagocytic system 
(MPS), resulting in accumulation in the Kupffer cells of the liver and the macrophages of the 
spleen.  This unique biodistribution generally results in lower systemic toxicity of 
nanotherapeutics. Additionally, nanoparticles can be engineered to incorporate multiple types 
of therapeutic or diagnostic agents, allowing for the synergistic therapeutic efficacy and real-
time monitoring of therapeutic response.  The promise of nanoparticle therapeutics is 
validated with the clinical success of multiple entities such as Doxil and Abraxane.4 
The story of nanoparticle therapeutics cannot, however, be considered an 
unblemished success as clinically deployed nanotherapeutics have limitations. For example, 
Doxil has an improved safety profile, but not better efficacy, compared to doxorubicin.5-6 
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Abraxane shows improved efficacy compared to paclitaxel, but it is extremely expensive to 
manufacture and generally has not replaced paclitaxel clinically.4, 7 Most nanocarriers can 
only be used to deliver drugs with specific properties (e.g., charge, hydrophobicity, etc) and 
have a fairly low threshold for drug incorporation, typically a few weight percent of active 
pharmaceutical ingredients (API). Most nanomedicines are in fact composed mostly of non-
API components.  The commercialization of nanotherapeutics is also hamstrung by high 
production costs and persistent manufacturing issues such as scalability to multi-kilogram 
batches and batch-to-batch consistency.  The toxicological impact and biological persistence 
of many nanoparticles remain poorly investigated, posing long term issues from exposure to 
these materials.8 
The nanoparticle platforms that have been extensively explored for biomedical 
applications are predominantly either purely inorganic or organic materials.  The archetypical 
inorganic nanoparticles, quantum dots (QDs), are nanomaterials generally composed of 
elements from either groups II and VI or III and V.9-13  They display unique optical 
properties, including sharp and symmetrical emission spectra, high quantum yields, broad 
absorption spectra, good chemical and photo-stability, and tunable size-dependent emission 
wavelengths.11  As a result, they have been evaluated extensively for use as optical imaging 
probes both in vitro and in vivo.  Another class of inorganic nanoparticles that have been 
evaluated for biomedical imaging applications are metal oxides, such as superparamagnetic 
iron oxide nanoparticles (SPIO).  Iron oxide nanoparticles have been used as contrast agents 
for magnetic resonance imaging (MRI), and one formulation of SPIO has received FDA 
approval for clinical use.14  Gold nanoparticles with controllable morphologies have been 
extensively used for biological imaging applications as they can be engineered to exhibit 
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strong absorption in the NIR region.15-17  Gold nanoparticles have also been explored for 
photothermal therapy, where absorbed light by small gold nanoparticles (10-30 nm) is 
rapidly converted into thermal energy, leading to hyperthermia and cell death.    
 Purely organic nanoparticles have also found widespread use as imaging and 
therapeutic agents.  Liposomes have been the most successful nanoparticle platform for 
biomedical applications, with several formulations clinically available.18-19 These 
nanoparticles are composed of an aqueous core surrounded by a phospholipid bilayer and 
have been used to deliver a variety of therapeutic and imaging agents.20-23 Surface 
modification of the lipid bilayer allows for long in vivo circulation times and targeting to 
specific regions.24  There have been many reports on the use of polymeric hydrogel 
nanoparticles as delivery vehicles for imaging contrast agents and therapeutics.25-35  
Dendrimers and other hyper-branched organic polymers have also been extensively evaluated 
for their potential in imaging and drug delivery applications.36-40  
 Hybrid nanoparticles are composed of both inorganic and organic components that 
can not only retain the beneficial features of both inorganic and organic nanomaterials, but 
also possess unique advantages over the other two types.  For example, the ability to combine 
a multitude of organic and inorganic components in a modular fashion allows for systematic 
tuning of the properties of the resultant hybrid nanomaterial.  This chapter will cover two 
major classes of hybrid nanomaterials, namely silica-based nanomaterials and nanoscale 
metal-organic frameworks (NMOFs), which have been recently explored for therapeutic 
applications.  While many nanoparticle platforms may be considered hybrid, we have chosen 
to restrict our discussion to silica-based nanomaterials and NMOFs that are closely examined 
in our laboratory for biomedical applications.   
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There are two major types of silica-based hybrid nanomaterials, solid silica particles 
and mesoporous silica nanoparticles (MSNs).  Unlike solid silica particles, MSNs exhibit 
many unique properties such as high surface areas, tunable pore sizes, and large pore 
volumes. Imaging or therapeutic cargoes can either be directly incorporated in the silica 
matrix or grafted to the outer surface of the solid silica particles.  MSNs can be 
functionalized with imaging or therapeutic agents in several ways, including loading of cargo 
into the pores, covalent grafting, and co-condensation of siloxy-derived cargoes.   
NMOFs, also termed nanoscale coordination polymers (NCPs), are a new class of 
hybrid nanomaterials crafted from metal connecting points and organic bridging ligands. 
These materials can be tailored for biomedical applications by direct incorporation of 
functionalities into the framework or via post-synthesis modification of an existing 
framework structure.41-44  Due to the presence of tunable pores and channels in many types of 
NMOF materials, it is also possible to encapsulate hydrophobic or charged agents into 
NMOFs through noncovalent interactions.45-48  This chapter highlights recent advances in the 
design and synthesis of hybrid silica and NMOF nanoparticles and their applications in 
cancer chemotherapy. 
1.2 Synthesis and Functionalization of Hybrid Nanomaterials 
1.2.1 Silica Nanomaterials 
The synthesis and functionalization of silica nanoparticles has been extensively 
reviewed elsewhere;49-51 only the synthetic strategies will be briefly discussed here.  Two 
major strategies are used to synthesize silica nanoparticles: the sol-gel synthesis and reverse 
microemulsion synthesis.  The sol-gel synthesis of monodisperse solid silica particles ranging 
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in size from 50 nm to 2 µm was first reported in 1968 by Stöber and co-workers.52  This 
method involves the controlled hydrolysis and condensation of a silica precursor, such as 
tetraethyl orthosilicate (TEOS), in ethanol using ammonia as a catalyst (Figure 1-1a).  The 
particle size can be tuned by adjusting the reaction conditions.  For example, adjusting the 
TEOS concentration from 0.05 M to 0.67 M while keeping the other reactant conditions 
constant affords silica particles from 20 to 880 nm in size.53  These particles remain stable in 
solution due to electrostatic repulsion from the negatively-charged silica particles.  Another 
common method for the synthesis of monodisperse silica nanoparticles uses reverse phase, or 
water-in-oil, microemulsions (Figure 1-1b).53-56  Reverse phase microemulsions are highly 
tailorable systems that consist of nanometer-sized water droplets stabilized by a surfactant in 
a predominantly organic phase.  The micelles in the microemulsion essentially act as 
“nanoreactors” that assist in controlling the kinetics of particle nucleation and growth.  The 
size and number of micelles within the microemulsion can be tuned by varying the water to 
surfactant ratio (W).  This method allows for careful control of particle size and 
polydispersity.  The reverse microemulsion method is superior to the Stöber method for 
making monodisperse silica nanoparticles smaller than 100 nm.  
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 Figure 1-1: Methods for synthesizing solid silica nanoparticles. (a) The Stöber method, in which 
the hydrolysis and condensation of TEOS is facilitated by base in ethanol/water: TEM micrograph 
shows 125 nm silica nanoparticles.57  (b) The reverse phase microemulsion, in which TEOS is 
hydrolyzed at the micellar interface and enters the aqueous droplet to form a silica nanoparticle within 
the micelle. TEM micrograph shows 37 nm silica nanoparticles.56 The scale bars indicate 200 nm. 
 Solid silica nanoparticles can be functionalized for drug delivery using several 
strategies.  The simplest method is to entrap hydrophillic functional molecules within the 
silica matrix via noncovalent interactions.  This method was widely used to incorporate 
luminescent dyes (such as the cationic fluorophore Ru(bpy)32+) within the anionic silica 
matrix.58  However, the entrapped molecule can leach out of the nanoparticle under 
physiological conditions, limiting the stability and utility of the nanoconstruct.  Alternatively, 
therapeutic agents can be covalently incorporated into silica nanoparticles by using 
trialkoxysilane-derived molecules that contain suitable moieties.  These molecules are 
incorporated within the silica matrix through silanol linkages during particle synthesis, 
leading to stable hybrid silica nanoparticles with agents incorporated uniformly throughout 
the silica matrix.  The silica nanoparticles can also be post-synthetically modified by reacting 
with trialkoxysilane molecules to introduce an active agent or functional group.  Post-
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synthesis grafting is particularly useful for modifying the particle surface selectively. The 
synthetic versatility also allows the incorporation of different cargoes in multi-step 
sequences.   After the desired organic functionality is attached to the silica nanoparticles, the 
nanoparticles can be further modified using traditional conjugation chemistry.  For example, 
an amine-modified particle can be reacted with various carboxylate-containing molecules to 
form a stable amide bond.  The cargoes can also be conjugated to the nanoparticle surface by 
electrostatic interactions.   Another popular strategy is to create a core-shell nanoparticle of a 
small inorganic nanoparticle or nanoparticles embedded within a silica matrix. 59-61  
1.2.2 Mesoporous Silica Nanoparticles 
MSNs are typically synthesized using a surfactant-templated sol-gel method (Figure 
1-2). 62-63  They provide a unique platform for the development of hybrid nanoparticles due to 
their high surface areas and tunable pore structures.  MCM-41 type materials, for example, 
possess a hexagonal array of one dimensional channels with diameters that can be tuned from 
2–10 nm.64  Synthetic procedures have been developed for controlling the morphologies of 
MCM-41 materials,65-66 leading to mesoporous silica nanospheres with diameters ranging 
from 60 to 1100 nm that have been utilized in a variety of applications, including catalysis,67-
68 drug delivery,69-70 and imaging.71-75  
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Figure 1-2: Schematic demonstrating the synthesis of MCM-41 type MSN particles. The 
cationic surfactant molecules self-assemble into hexagonal arrays in aqueous solution and the 
silica precursors then hydrolyze and condense along the exterior of the micelles to form a 
mesoporous material after surfactant removal.  
MSNs can be covalently functionalized using two different approaches, either via co-
condensation or by post-synthesis grafting.  Victor Lin and coworkers have reported a co-
condensation method for incorporating various organic functional groups into the pores of 
MSN.63, 76-77 This co-condensation method has been extended in our lab to incorporate 
gadolinium chelates for MRI imaging.74  The desired triethoxysilane is condensed into the 
walls of the MSNs during synthesis of the nanoparticle resulting in the uniform incorporation 
of the organic functionality throughout the particles. The degree of functionalization and 
particle size can be modified by adjusting the reagent concentration, size, and the 
hydrophobicity or hydrophillicity of the co-condensing reagents.  However, not all types of 
MSN nanoparticles can be made by this method, as the organically-modified triethoxysilane 
can destabilize the surfactant templates during the synthesis, leading to large, rod-like 
particles (≈1000 nm).77  The organic functionality can also have a pronounced effect on the 
pore structure of the nanoparticle.  
Alternatively, as-synthesized MSNs can be functionalized via post-synthesis 
modification, for example, by reacting MSN nanoparticles with a variety of trialkoxysilanes 
to affect condensation with silanol groups on the silica surface.  This method allows the 
particle morphology and pore structure to remain intact, but has been found to result in 
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inhomogeneous surface coverage of the nanoparticle, as the particle exterior surface and pore 
entrances are kinetically more accessible.  This feature can also be exploited to selectively 
modify the exterior surface of the nanoparticles before the extraction of the surfactant in the 
channels.  The surfactant is then removed and the interiors of the pores can then be 
differentially functionalized. The organically-modified MSN nanoparticles can be further 
modified with biomedically-relevant molecules. 
1.2.3 Nanoscale Metal-Organic Frameworks 
As the synthesis of nanoscale and microscale MOFs has recently been reviewed,42, 44, 
78 only general synthetic strategies will be outlined here. Four general methods have been 
utilized to synthesize NMOFs: nanoprecipitation, solvothermal, reverse microemulsion, and 
surfactant-templated solvothermal. The first method tends to yield amorphous materials, 
while the latter three methods can afford crystalline materials, owing to the ability to exert  
better control on nanoparticle nucleation and growth kinetics. The first two methods are 
surfactant free, whereas the last two methods rely on surfactants not only to control the 
particle synthesis but also to stabilize these particles.  
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Figure 1-3: a) Surfactant-free synthesis of NMOFs by mixing NMOF precursors in 
appropriate solvents. In the nanoprecipitation method, the NMOF forms rapidly at room 
temperature, whereas in the solvothermal method, heating the solution leads to more 
controlled particle growth. b) and c) SEM images of amorphous79 or crystalline80 NMOFs.  
In a typical NMOF synthesis, precursor solutions are mixed together to allow particle 
nucleation and growth (Figure 1-3a). In the nanoprecipitation method, nanoparticles form 
because the particles are insoluble in the solvent system whereas the individual precursors 
remain soluble. Due to the rapid particle growth, NMOFs produced by this method tend to be 
amorphous (Figure 1-3b). Solvothermal synthesis of NMOFs can be achieved with either 
conventional or microwave heating. Because high reaction temperatures are involved in the 
solvothermal method, more extensive transformations of the precursors typically occur 
before NMOF nanoparticle formation and favor the creation of more stable crystalline 
materials (Figure 1-3c). Temperature and heating rate provide additional parameters to 
control NMOF particle nucleation and growth.  Surfactant-assisted synthesis of NMOFs can 
be carried out at either room or elevated temperatures. Because the building blocks for 
NMOFs are typically water soluble, reverse microemulsions provide another method to 
control the nucleation and growth kinetics of NMOF particles. Reverse microemulsions are 
formed by using surfactants to stabilize water droplets within a nonpolar organic phase 
(Figure 1-4a).  Surfactant molecules can also be used to template the NMOF synthesis under 
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solvothermal conditions (Figure 1-4a) by coating the surfaces of growing NMOF particles.  
Surfactant molecules play an important role in defining NMOF morphologies. The four 
general methods described above have been adopted to synthesize a variety of NMOFs. With 
the ability to independently adjust NMOF precursors, reaction solvents, pH values, 
temperatures, surfactant or other templating molecules, W values, and other parameters, a 
range of NMOFs with well-defined compositions and morphologies have been synthesized. It 
has also been shown that surface termination can be an important parameter in defining 
NMOF morphologies.46, 81 Although the synthesis of NMOFs has been phenomenologically 
described, there is little study on the NMOF growth mechanism and kinetics.  Fundamental 
understanding of NMOF growth mechanism and kinetics will facilitate the development of 
NMOFs as a promising class of hybrid nanomaterials for biological and biomedical 
applications. 
 
Figure 1.4: a) Surfactant-templated NMOF synthesis, either conducted with reverse 
microemulsions at room temperature or surfactant-assisted solvothermal reactions. b)82 and 
c)83 show SEM images of crystalline NMOFs synthesized by these methods. 
 
 NMOF materials tend to dissociate rapidly in aqueous media, so they must be 
stabilized to increase their utility in biological applications. Our group was able to 
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encapsulate NMOFs within a silica shell.79-80, 84-86 Briefly, the as-synthesized NMOFs were 
treated with polyvinylpyrollidone, then coated with a shell of amorphous silica in basic 
ethanol. The silica shell thickness could be controlled by varying the reaction parameters and 
the silica shell could be further functionalized with a variety of silyl-derived molecules. An 
alternative procedure to coat NMOFs with silica also was developed using sodium silicate as 
the silica source in aqueous media for NMOFs that are unstable under basic conditions.80 The 
silica shell could significantly retard, but not entirely prevent, NMOF decomposition. Our 
group has also developed a method to coat NMOFs with a lipid bilayer.87 The lipid bilayer 
could drastically improve the stability of NMOFs under physiological conditions and could 
be functionalized to contain additional moieties (targeting molecules, fluorescent dyes). 
Several groups have demonstrated the coating of NMOFs with biocompatible polymers via 
coordination to surface metal centers. 46, 88-89 These polymers could be used to increase 
NMOF stability, improve biocompatibility, and modulate MRI relaxivity. Additional active 
agents or targeting molecules could be conjugated to the NMOF through these polymers. 
1.3 Therapeutic Applications of Hybrid Materials 
1.3.1 Silica Based Materials  
Hybrid silica nanoparticles have been used in drug delivery and therapy applications.  
Prasad and coworkers described the use of an organically-modified silica nanoparticle for 
photodynamic therapy (PDT).90  PDT is a light-activated treatment for cancer and other 
diseases, and works by utilizing light sensitive drugs (i.e. photosensitizers) that can be 
preferentially localized in malignant tissues.  PDT’s therapeutic effect is initiated by 
photoexcitation of the localized photosensitizer to generate cytotoxic species such as singlet 
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oxygen (1O2). This leads to selective and irreversible destruction of diseased tissues, without 
damaging adjacent healthy ones. The main drawback to this therapy is that currently 
approved PDT photosensitizers absorb in the visible spectral region below 700 nm, where 
light penetration into the skin is only a few millimeters.  This problem can be overcome by 
combining a two-photon absorbing (TPA) dye with the photosensitizer. Here, the 
photosensitizer is indirectly excited through fluorescence resonance energy transfer (FRET).  
In this work, a known photosensitizer and a two-photon energy donor were co-encapsulated 
in a ~30 nm silica nanoparticle (Figure 1-5).  Upon two-photon irradiation, the 
photosensitizer is excited as a result of intraparticle FRET from the two-photon absorbing 
dye, resulting in the generation of singlet oxygen and other reactive oxygen species.  The 
uptake of these particles was demonstrated through fluorescence imaging of HeLa cells.  
Upon two-photon irradiation, HeLa cells that had been incubated with the nanoparticles 
exhibited drastic morphology changes associated with cell necrosis, apparently induced by 
the reactive oxygen species generated by the photosensitizer. Prasad and coworkers 
developed a similar system where a photosensitizer was covalently incorporated within a 20 
nm silica nanoparticle.91 These nanoparticles are rapidly taken up in vitro and demonstrate 
phototoxic action upon irridation. 
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Figure 1.5: Schematic showing an organically-modified silica nanoparticle co-encapsulating  
two-photon absorbing fluorescent dye aggregates and a photosensitizing drug for two-photon 
photodynamic therapy.90 
Silica nanoparticles have been extensively studied as DNA carriers for gene 
therapy.62, 92-96 For example, Prasad and coworkers have developed a fluorescently-labeled 
silica nanoparticle with a cationic surface coating.92, 95  Gel electrophoresis studies revealed 
that the particles efficiently bind DNA via electrostatic interactions and prevent enzymatic 
degradation of the encapsulated DNA.  Confocal microscopy studies revealed that the 
nanoparticles were internalized by cells in vitro with the released DNA migrating to the 
nucleus.  Further in vivo studies showed that the particles were able to successfully transfect 
and modulate the activity of neural cells in a murine model.92  The transfection efficiency 
was equal to or exceeded that of a viral vector and no particle-related toxicity was observed 
after 4 weeks. 
  Jiang and coworkers have reported a system of hollow chitosan-silica nanospheres 
fabricated in aqueous medium.97  The anticancer drug doxorubicin was loaded within the 
interior of the nanosphere (8.9 wt %).  Drug release was found to be pH sensitive, with 
minimal release occurring at pH = 7.4; however, the drug is rapidly released at pH=4.  
Preliminary cytotoxicity assays demonstrated that the nanoparticles were more effective than 
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doxorubicin, presumably by more efficient drug uptake. A similar chitosan-silica nanosphere 
system was used for the treatment of breast cancer in vitro and in vivo with tumor necrosis 
factor alpha (TNF-α).98 TNF-α was electrostatically bound to the nanosphere and a targeting 
antibody was covalently attached to the surface. The TNF-α conjugated nanospheres 
possessed time and concentration dependent cytotoxic effects on MCF-7 breast cancer cells 
(Figure 1-6) with targeting increasing nanoparticle localization to the cell surface. In vivo 
assays using a breast cancer xenograft model demonstrated that nanoparticle-bound TNF-α 
enhanced tumor growth inhibition compared to free TNF-α or the non-treated control.  
Corma and coworkers have developed liposomal doxorubicin nanoparticles with a 
poly(silsesquioxane) shell.99  In vitro assays against human glioma cells demonstrated that 
the nanospheres were able to kill the cells, reaching mortality rates of 44%, compared to 90% 
for the free drug.  Fluorescence microscopy images revealed that the nanospheres enter the 
cells and release doxorubicin. Botella and coworkers designed a silica nanoparticle-based 
system for the systemic delivery of the anticancer drug camptothecin.100 Camptothecin was 
covalently linked to the nanoparticle surface, which was further modified to contain a 
fluorescent dye. The nanoparticle-conjugate showed minimal background release. 
Preliminary in vitro cytotoxicity assays revealed that the nanoparticles were efficiently 
internalized by cells, but the efficacy of the nanoparticle conjuagate was less than free 
camptothecin. In vivo biodistribution and efficacy studies were performed in colon cancer 
xenografts. Nanoparticle conjugation increased tumor camptothecin concentration compared 
to the free drug. Additionally, nanoparticle-delivered camptothecin treatment delayed tumor 
growth and reduced side effects compared to free camptothecin.  
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Figure 1-6: Cytotoxicity of TNF-α loaded chitosan-silica nanospheres. a) Cytotoxicity effect 
of TNF-α loaded chitosan-silica nanospheres at the same concentration (500 ng/mL TNF-α) 
with different incubation times. b) Concentration dependent cell viability of TNF-α loaded 
chitosan-silica nanospheres incubated for 4 hours. c) Fluorescent photos of MCF-7 cells 
demonstrating the time-dependent cytotoxicity effect of the nanocarriers by acridine orange 
(green color, live cells) and propidium iodide (red color, dead cells) staining. D) Fluorescent 
photos of MCF-7 cells demonstrating concentration dependent cytotoxicity effect after 48 
hours incubation by acridine orange and propidium iodide stain. Scale bar is 50 µm.98  
 
1.3.2 Mesoporous Silica Nanoparticles  
 Due to their unique properties, mesoporous silica nanoparticles have been extensively 
evaluated as drug delivery vehicles. Victor Lin and coworkers first demonstrated the use of 
MCM-41 nanoparticles for the delivery of a membrane impermeable protein, cytochrome 
C.69  After removing the surfactants from large-pore (5.4 nm) MSN particles, cytochrome C 
(maximum loading = 41.5 wt%) was loaded into the pores.  The release of the protein was 
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measured in PBS at two different pH values (7.4 and 5.2) over a 25 hour period.  The total 
percentages of proteins that were released were 45 and 55% at pH values of 7.4 and 5.2, 
respectively.  The difference in release was attributed to the extent of negative charge on the 
MSN surface, which favorably interacts with the positively-charged protein.  No significant 
release of the protein was detected within the first 4 hours at pH 7.4, which allowed for the 
introduction of protein-loaded particles into cell culture at physiological pH without losing a 
large amount of the entrapped protein due to burst release.  The released cytochrome C was 
found to retain catalytic activity for the oxidation of 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonate) (ABTS) by hydrogen peroxide.   HeLa cells could internalize the loaded MSN 
particles and confocal microscopy showed escape of the protein from endosomal entrapment.  
MSN systems were also used to deliver cysteine to cells.101  The covalently attached cysteine 
does not release from the MSNs in the absence of a reducing agent; however, all cysteine 
was released within 1 h after the addition of a suitable reducing agent.  In vitro assays against 
HeLa cells demonstrated that the conjugated nanoparticle was 444 times more effective in 
inhibiting cell growth than N-acetylcysteine, the standard molecule for cysteine therapy.   
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Figure 1-7: Schematic of the Au nanoparticle-capped MSN-based drug delivery system. The 
controlled release of the cargo is based on UV irradiation.102 
 
Victor Lin and coworkers pioneered the development of MSN-based drug delivery 
systems where the nanoparticle pores are capped by a stimuli-responsive system to allow 
controlled cargo release.102-104  As an example shown in Figure 1-7, the gold nanoparticles 
were conjugated to the MSN materials with a photolabile linker.102  The hybrid system will 
release the Au nanoparticle pore caps when exposed to UV irradiation.  This system was used 
to deliver paclitaxel to human liver and fibroblast cells.  After UV irradiation, significant 
decreases in cell viability were observed.  Other drug molecules and neurotransmitters, such 
as vancomycin and adenosine triphosphate (ATP), have also been delivered using this 
strategy.103-104  
A double drug delivery system was also developed based on capped MSN 
nanoparticles.105  Boronic acid functionalized MSN nanoparticles were loaded with cyclic 
adenosine monophosphate (cAMP), an important cellular signaling molecule.  The pores of 
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synthesized by incorporating 3-[2-(2-aminoethylamino)ethylamino]propyltriethoxysilane into 
the silica framework, and was then fused with anionic (DOPS) liposomes.  
Subsequently, the protocell system was adapted for the delivery of small molecule 
chemotherapeutics.111 A variety of different chemotherapeutic drugs and drug cocktails were 
loaded into the pores of a mesoprous silica nanoparticle before liposome coating. The 
protocell was modified with a targeting peptide for hepatocellular carcinoma. Targeting 
increased protocell uptake nearly 10,000 times in tumor cells compared to heptacytes, 
immune cells, and endothelial cells. In vitro assays demonstrated the protocells could 
improve treatment efficacy of multidrug-resistant hepatocellular carincoma by 106. The 
protocell system was also adapted for gene delivery.112  Cationic liposomes were fused with 
solid silica nanoparticles of 30, 50, 80, and 130 nm in diameter to form silica-supported lipid 
bilayers.  These particles were shown to bind to plasmid DNA in a size dependent manner, as 
measured by gel electrophoresis.  It was observed that the transfection efficiency in the CHO 
cells decreased with particle size, with the 130 nm particles exhibiting no DNA transfection.  
Confocal microscopy studies revealed that the DNA needed to be released from the construct 
to induce transfection.  For larger nanoparticles, the DNA appears to be trapped on the silica 
nanoparticles and does not leave the endosomal compartment, resulting in the lack of activity 
for the 130 nm nanoparticles. These protocell constructs protected the DNA from enzymatic 
degradation.   
1.3.3 Nanoscale Metal-Organic Frameworks  
Our group has developed two NMOF platforms to deliver cisplatin-based 
chemotherapeutics.79-80   The first NMOF was built from a cisplatin prodrug (c,c,t-
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Pt(NH3)2Cl2(succinate)2)  and Tb3+ ions using a nanoprecipitation procedure. This cisplatin 
NMOF was coated with a thin layer of silica and targeted to cancer cells with a silyl-derived 
peptide. When placed in physiological medium, the framework decomposes and the cisplatin 
prodrug diffuses through the silica shell in a controlled manner (Figure 1-10a).  The targeted 
peptide possessed similar cytotoxicity against human colon cancer cells as cisplatin, while 
the uncoated or untargeted NMOFs were less effective, presumably due to decreased uptake 
via receptor mediated endocytosis.  
 
Figure 1-10: a) Schematic representation of the synthesis, post-synthetic modification and 
cisplatin release from Tb3+ based NMOF.79 b) Schematic representation of the synthesis, 
post-synthetic modification, silica coating, and agent release from iron-carboxylate MIL101 
NMOFs.80 
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Our group has also demonstrated a post-synthesis modification scheme to introduce 
therapeutic and imaging moieties into the iron-carboxylate NMOF, MIL-101 (Figure 1-
10b).80 Highly porous MIL-101 nanoparticles with amine-functionality were synthesized 
using a solvothermal method with microwave heating.  A cisplatin prodrug, c,c,t-
Pt(NH3)2Cl2(OEt)(succinate) was also covalently incorporated into the framework via an 
amide linkage between the amine groups in the framework and the carboxylate of the anti-
cancer prodrug.  These nanoparticles were encapsulated in amorphous silica and tested in 
vitro against HT-29 human colon adenocarcinoma cells.  Treatment of the cells with the Pt-
loaded MIL-101 showed appreciable cytotoxicity (IC50 = 29 μM), but not as much as 
cisplatin under the same conditions (IC50 = 20 μM).  Targeting of the nanoparticles with a 
silyl-derived cyclic RGD peptide as a targeting moiety increased the cytotoxicity to a value 
comparable to cisplatin (IC50 = 21 μM).  An optical imaging agent, 1,3,5,7-tetramethyl-4,4-
difluoro-8-bromoethyl-4-bora-3a,4a-diaza-s-indacene (Br-Bodipy) was loaded into the 
framework by covalent attachment to the amine groups in the framework. The Bodipy-loaded 
MIL-101 labeled colon cancer cells in a dose-dependent manner.  
Horcajada and coworkers have developed a group of porous NMOF carriers for both 
drug delivery and imaging.46  They synthesized five iron-carboxylate NMOFs under aqueous 
conditions (corresponding to the previously reported MIL-89, MIL-101_NH2, MIL-88A, 
MIL-100, and MIL-53 bulk phases).  These frameworks were rendered more biocompatible 
by coating with PEG, dextran, or chitosan.  The MIL-88A particles showed low in vitro 
toxicity against murine macrophage cells (IC50 = 57 μg/mL).  The in vivo toxicity of MIL-
88A, MIL-100, MIL-88Bt was determined using the highest injectable amount (up to 220 
mg/kg) in a rat model.  Aside from a small increase of liver and spleen weights observed at 
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the onset of the study (which returned to control levels after a short period of time), no signs 
of toxicity were observed for 3 months.   
These NMOFs were also evaluated as potential drug carriers.  Four different anti-
cancer or antiviral drugs (busulfan, azidothymidine triphosphate, cidofovir, and doxorubicin) 
were loaded into the NMOF pores via noncovalent interactions.  This drug loading was 
highly efficient, with up to 90 wt% loading for azidothymidine triphosphate (AZT) into MIL-
101_NH2 particles.  Release profile studies using MIL-100 nanoparticles loaded with 
cidofovir, doxorubicin, and AZT showed sustained release with no burst effects.  The 
potential applicability of these NMOFs as drug delivery vehicles was evaluated in vitro.  
Experiments using human leukemia and myeloma cells showed that MIL-100 nanoparticles 
loaded with busulfan displayed comparable cytotoxicity to the free drug.   Further in vitro 
tests using MIL-100 nanoparticles loaded with AZT showed significant anti-HIV activity 
only for those nanoparticles loaded with the active drug, with the nanocarrier showing no 
significant activity over the same concentration range.  
The particle systems were also evaluated as T2-weighted MRI contrast agents.  
Mössbauer spectroscopy demonstrated that the NMOFs themselves, not any iron oxide or 
hydroxide decomposition products, acted as the contrast agents and had r2 values up to 95 
mM-1 s-1 for MIL-88A-PEG NMOFs.46  In vivo studies using Wistar rats demonstrated that 
the particles showed negative contrast in the major RES organs (liver and spleen) 30 minutes 
post injection of MIL-88A nanoparticles.  This contrast disappeared 3 months post injection.  
Our group has also developed a NMOF platform to deliver the chemotherapeutic 
methotrexate.87 Methotrexate was incorporated into 3 different NMOF platforms at very high 
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drug loadings  (up to 79.1 wt%), utilizing zinc, zirconium or gadolinium  metal centers. The 
gadolinium-methotrexate NMOF could then be encapsulated within a functionalized lipid 
bilayer. In vitro assays demonstrated that the lipid-coated and targeted methotrexate NMOF 
had superior cytotoxicity to methotrexate in a leukemia cell line.  
1.4 Theranostic Applications of Hybrid Nanomaterials 
 One of the unique advantages of nanomaterials over conventional small molecule 
therapeutics is the ability to incorporate multiple types of agents within the same 
nanoparticle. A popular trend is to create theranostic materials, which incorporate both an 
imaging contrast agent and a therapeutic agent. 113 Theranostic nanoparticles allow for the 
real-time monitoring of nanoparticle biodistribution, tumor uptake, tumor distribution and 
treatment efficacy. Someday, theranostic nanomaterials could provide clinicians important 
information as they attempt to assess the progress of chemotherapeutic treatments. 
1.4.1 Silica Based Materials  
Hai and coworkers prepared 105 nm silica particles with entrapped methylene blue 
(MB) dye for near-IR (NIR) imaging and photodynamic therapy.114 Methylene blue is an 
effective photosensitizer due to its high quantum yield of 1O2 generation, low dark toxicity, 
and wide NIR therapeutic window.  PDT was demonstrated in vitro against HeLa cells.  
Significant cell death was only observed in cells treated with the MB nanoparticles and laser 
irradiation, with little toxicity observed when the cells were treated with either the 
nanoparticles or the laser alone.  Both fluorescence imaging and PDT was observed in vivo in 
a mouse xenograft model.  After intratumoral injection of the MB nanoparticles, fluorescent 
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imaging of the mice revealed that the tumor region was clearly defined and, after laser 
treatment, the tumor became necrotic (Figure 1-11).  
 
Figure 1-11: a) Images of control mice and the two subcutaneous injections of 100 µL MB-
encapsulated PSiNPs with concentrations of 44 mg/mL (a) and 4.4 mg/mL (b). The 
acquisition was performed two minutes post-injection. b) Real time in vivo images of mice 
i.v. injected with 200 µL of MB-encapsulated PSiNPs (44 mg/mL) at different time points 
post-injection.114  
 Prasad and coworkers developed a novel drug carrier system for photodynamic 
therapy.115 Organically-modified silica nanoparticles were used to encapsulate the 
photosensitizing anticancer drug 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide within the 
core of the nanoparticle. In vitro cell uptake studies demonstrated that the nanoparticles were 
internalized by HeLa cervical cancer cells and were found throughout the cytoplasm. 
Cytotoxicity studies with two different human cancer cell lines demonstrated that the 
photosensiziter-loaded nanoparticles displayed significant cytotoxic effects after laser 
irradiation and showed no toxicity in the absence of laser light. The unloaded silica 
nanoparticles demonstrated no toxic effects as well. 
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1.4.2 Mesoporous Silica Nanoparticles  
Hyeon and coworkers synthesized particles containing a single iron oxide 
nanoparticle coated with a mesoporous silica shell. 71 SPIO nanoparticles provide T2-weighed 
MR contrast enhancement, while the mesoporous silica serves as a drug carrier.  Fluorescent 
dyes were also covalently attached to the silica shell and the anticancer drug doxorubicin was 
loaded into the pores.  Preliminary in vitro assays revealed that the carrier possessed minimal 
cytotoxicity to cancer cells, while the doxorubicin-loaded nanoparticles showed a dose 
dependent cytotoxicity profile.  In vivo assays on a murine xenograft model showed strong T2 
signal reduction at the tumor site up to 24 hours post injection, which was confirmed by ex 
vivo organ analysis by fluorescence microscopy (Figure 1-12). Hyeon and coworkers created 
a MSN nanoparticle capable of simultaneous drug delivery, MR imaging and fluorescent 
imaging.116 Dye-doped MSN nanoparticles were surface functionalized with smaller iron 
oxide nanoparticles and the anticancer drug doxorubicin was loaded into the materials’ pores. 
MRI relaxivity measurements demonstrated that the iron oxide@MSN nanoparticles 
possessed higher T2 relaxivity than the iron oxide nanocrystals alone.  The iron oxide@MSN 
nanoparticles were efficiently internalized into cells in vitro as measured by fluorescent 
imaging, Prussian blue staining, and MR imaging. The doxorubicin-loaded nanoparticles 
possessed similar cytotoxicity as free doxorubicin.  In vivo, the MSN nanoparticles had high 
tumor accumulation and could be imaged by both MR and fluorescent imaging. Doxorubicin 
could also be delivered to the tumor region, but no tumor growth inhibition data was 
presented. In a subsequent publication, this system was modified to covalently attach  
doxorubicin to the MSN.117 
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Figure 1.12: a) In vivo T2-weighted MR and b) fluorescence images of subcutaneously 
injected MCF-7 cells labeled with Fe3O4@MSN and control cells. (c) T2-weighted MR 
(upper row) and color maps (lower row) of the tumor before and after the Fe3O4@MSN 
particles were intravenously injected into the tail vein of a nude mouse implanted with MCF-
7 cells.  A decrease in signal intensity was detected at the tumor site (arrows).  (d) 
Photographic (left) and fluorescence (right) images of several organs and the tumor 24 hours 
after i.v. injection.71 
    A similar report by Zink and coworkers described the encapsulation of SPIO 
nanocrystals inside mesostructured silica spheres that were labeled with fluorescent dye 
molecules and coated with hydrophilic groups (trihydroxysilylpropyl methylphosphonate) to 
prevent aggregation.72  Water-insoluble anticancer drugs (camptothecin and paclitaxel) were 
delivered to human cancer cells; surface conjugation with cancer-specific targeting agents 
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increased the uptake into cancer cells relative to that in non-cancerous fibroblasts. Zink and 
coworkers studied this system in vivo in a murine xenograft model.118 The biodistribution of 
the fluorescent MSN nanoparticles was evaluated by ICP-MS, histology, and fluorescent 
imaging. The nanoparticles were well tolerated and showed preferential tumor uptake.  
Camptothecin-loaded MSNs demonstrated statistically significant tumor growth inhibition 
compared to campthecin alone, while the unloaded nanoparticles did not affect tumor growth.   
Chou, Chi, Hsiao, and coworkers have developed a multimodal system for MR 
imaging and photodynamic therapy.119  Silica-coated SPIO nanoparticles were functionalized 
with an iridium photosensitizer and were evaluated in vitro.  Confocal microscopy 
experiments revealed that the nanoparticles were efficiently uptaken by HeLa cells in a dose-
dependent fashion.  The nanoparticles also provided adequate T2-weighted contrast using a 
1.5 T scanner.  Cytotoxicity assays revealed that the as-synthesized nanoparticles were not 
cytotoxic in the absence of irradiation; however, they exhibited significant cell death upon 
irradiation.  
1.4.3 Nanoscale Metal Organic Frameworks  
  Boyes and coworkers have developed a multimodal system based on the NMOF 
particles developed in our group for targeted imaging and treatment of cancer.89  
Gadolinium-based NMOF particles were synthesized as described previously by our group82 
and were functionalized with PNIPAM-co-PNSOS-co-PFMA copolymers via vacant 
coordination sites on the Gd3+ metal centers.  A chemotherapeutic, methotrexate (MTX), and 
a targeting peptide, glycine-arginine-glycine-aspartate-serine-NH2 (GRGDS-NH2), were 
conjugated to the copolymer.  Preliminary in vitro assays were performed on canine FITZ-
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HSA cells.  Confocal microscopy experiments demonstrated that the targeted nanoparticles 
had significant localization at the cell surface after 1 hour of incubation, with internalization 
observed after 24 hours, while the unmodified nanoparticles had no significant fluorescence 
over the same time period.  Cell growth inhibition studies demonstrated that the MTX-
containing nanoparticles show a dose-dependent inhibition of growth similar to the free drug.  
1.5 Conclusions 
 The effective delivery of chemotherapeutics to the tumor site remains a significant 
challenge for many difficult to treat cancers. Nanotherapeutics offer considerable promise in 
this area as they generally show higher tumor uptake, increased efficacy and reduced toxicity 
compared to their small molecule counterparts.  Hybrid nanomaterials, combining the 
advantageous properties of both inorganic and organic nanoparticles, are an intriguing class 
of nanotherapeutics. Preliminary investigations reveal that hybrid nanomaterials are highly 
efficacious drug delivery agents for the delivery of a variety of different therapeutic classes. 
Hybrid nanomaterials can also be developed as theranostic agents, combining both imaging 
and drug delivery functionalities.  However, many of these materials still need to undergo 
systemic in vivo investigation to fully realize their clinical potential as drug delivery vehicles.   
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Chapter 2: 
Polysilsesquioxane Nanoparticles for Targeted Oxaliplatin-Based Cancer 
Chemotherapy by Triggered Release 
2.1 Introduction 
 Since the discovery of cisplatin by Rosenberg in the 1960’s, platinum anticancer 
drugs have played an important role in cancer chemotherapy.1 Cisplatin is used to treat a 
variety of cancers such as testicular, lung, breast, and ovarian cancer. The success of cisplatin 
has led to the synthesis and biological evaluation of thousands of platinum complexes; 
however, only two additional complexes−carboplatin and oxaliplatin−are approved for 
clinical use by the FDA.2-4  The clinical efficacy of platinum-based anticancer drugs is 
limited by their poor pharmacokinetic properties. High doses of platins are needed, which 
often lead to severe side effects. Furthermore, many tumors display inherent or acquired 
resistance to platinum-based therapies. There exists a need to develop alternative strategies to 
effectively deliver, with fewer side effects, platinum drugs to the tumor. 
Nanomaterials offer one possible solution. Nanoparticulate imaging and therapeutic 
agents have several advantages over traditional small molecule agents, including high agent 
loading, tunable size, tailorable surface properties, controllable drug release kinetics, and 
improved pharmacokinetics. 5-12 Nanoparticles also tend to have increased accumulation in 
tumors as a result of the enhanced permeability and retention (EPR) effect that results from 
44 
 
the leaky tumor neovasculatures. Additionally, nanoparticles can be specifically targeted to 
cancer cells by surface conjugation of an appropriate ligand to further enhance their tumor 
accumulation. The clinical success of nanoparticle therapeutics such as Doxil illustrates the 
potential of nanomaterials in anticancer drug delivery. Our lab has previously developed 
nanoscale coordination polymers (NCP) as a potential delivery vehicle for cisplatin 
prodrugs.13-14 These materials demonstrated high agent loading and comparable cytotoxicity 
to cisplatin in vitro. However, these materials readily degrade under physiological conditions, 
limiting their potential for in vivo applications. We sought to develop a new nanoparticle 
platform which would possess minimal drug release and nanoparticle decomposition when 
circulating in the blood stream, but would also readily release the drugs upon cellular 
internalization. This chapter describes the development of bridged polysilsesquioxane (PSQ) 
nanoparticles as a platform for oxaliplatin delivery. 
PSQs are a type of hybrid material composed of silsesquioxane networks with organic or 
metal-organic bridging ligands. These materials are synthesized from bis-trialkoxysilanes 
[(R'O)3-Si-R-Si-(OR')3] by sol-gel chemistry.15-17 PSQs have been well studied as bulk 
materials for a number of applications, but have only recently been prepared as 
nanomaterials.18-22 PSQs offer similar biocompatiblity as silica-based materials, which have 
been extensively studied for biomedical applications.23-26 However, as a homopolymer of 
(R'O)3-Si-R-Si-(OR')3, PSQ materials allow much higher drug loadings than silica-based 
materials with grafted drugs only on their surfaces. The physicochemical properties of PSQ 
materials can be more easily tuned by changing the monomer properties than in a silica-based 
material. 
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The goal of this research is to develop PSQ nanoparticles for the delivery of platinum 
anticancer drugs based on the FDA-approved anticancer drug oxaliplatin. The development 
of these PSQ nanoparticles starts with the synthesis of a platinum(IV) precursor molecule. 
The platinum complex is then polymerized within an anionic reverse microemulsion to form 
the PSQ nanoparticles. The PSQ nanoparticles are then post-synthetically modified to include 
either a cancer targeting peptide or a passivating polymer. The functionalized nanoparticles 
are then evaluated in vitro against a panel of cancer cell lines and in vivo against two mouse 
xenograft models.  
2.2 Results and Discussion 
2.2.1 Synthesis of Platinum Complexes 
 The platinum(IV) complex Pt(dach)Cl2(triethoxysilylpropyl succinate)2 (dachPtSi, 
where dach = R,R-diaminocyclohexane) was synthesized starting from the readily available 
platinum(II) starting material, K2[PtCl4], by following established procedures with minor 
modifications (Scheme 2-1).27-30 First, K2[PtCl4] was converted into Pt(dach)Cl2 in high yield 
(typically ≈95 %) by a modification of Dhara’s procedure for the synthesis of cisplatin, going 
through an isolatable Pt(dach)I2 intermediate complex (Scheme 2-1, steps 1 and 2).27 
Pt(dach)Cl2 could then be oxidized to Pt(dach)Cl2(OH)2 with hydrogen peroxide in water 
(Scheme 2-1, step 3). The platinum complex dachPtSi was synthesized in 50-60% yield by 
reacting Pt(dach)Cl2(OH)2 with excess triethoxysilylpropyl succinic anhydride in DMSO 
(Scheme 2-1, step 4). The OH groups on Pt(dach)Cl2(OH)2 act as nucleophiles and add to the 
electrophilic carbonyl carbons within the anhydride. The dachPtSi monomer contains a 
platinum(IV) complex, which is known to be inert under non-reducing conditions, but will be 
rapidly reduced by endogenous molecules to the active Pt(II) complex.31 Additionally, 
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dachPtSi contains orthogonal carboxylic acid functionalities, which can be used to modify 
the nanoparticle post-synthetically. 
 
Scheme 2-1: Synthesis of platinum complexes used for the synthesis of the PSQ nanoparticle 
2.1. 
2.2.2 Synthesis of PSQ nanoparticle 2.1 
PSQ nanoparticles 2.1 were synthesized by base-catalyzed sol-gel polymerization in an 
anionic reverse microemulsion (Scheme 2-2). Briefly, dachPtSi (29 µmol) was dissolved in 
3.75 mL of ammonium hydroxide solution. This solution was then added to 125 mL of 0.3 M 
docusate sodium salt in hexanes. After 24 hours of reaction, the nanoparticles were 
precipitated from the reverse microemulsion by the addition of an equal volume of ethanol. 
Particles of 2.1 were isolated by centrifugation and washed repeatedly with ethanol. The 
particle size and morphology could be tuned by adjusting the reaction time, water to 
surfactant molar ratio (w), and the concentration of ammonia or Pt complex in the aqueous 
phase. The nanoparticles of 2.1 were characterized by transmission electron microscopy 
(TEM), dynamic light scattering (DLS), thermogravimetric analysis (TGA), and inductively-
coupled plasma mass spectrometry (ICP-MS). As shown in Figure 2-1, TEM analysis of 2.1 
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showed spherical nanoparticles of 50-100 nm in diameter. The nanoparticles appear to be 
aggregated on the TEM slides, but this aggregation is induced by solvent evaporation.  DLS 
measurements of 2.1 gave an average diameter of 78 nm (PDI: 0.074) (Figure 2-2, Table 2-
1). The zeta potential of 2.1 was -20.7 mV in PBS. TGA analysis gave 48% weight loss for 
the organics (Figure 2-3), which is slightly lower than 52% expected for the homopolymer of 
dachPtSi. We believe that the lower weight loss can be attributed to the presence of sodium 
ions in 2.1 (from the surfactant used in the synthesis), which was confirmed by energy 
dispersive X-ray spectroscopic (EDS) measurements. ICP-MS measurements of 2.1 gave a Pt 
loading of 18-24 wt% by weight (expected 24 wt% for the homopolymer), yielding an active 
agent loading [Pt(dach)Cl2] of 35-47 wt%. Each particle of 2.1 contains approximately 
1.5×105 Pt(dach)Cl2 molecules, which is several thousand times the drug loading of known 
nanoparticle platforms that deliver Pt(IV) prodrugs.32-36 
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Scheme 2-2: Schematic demonstrating the synthesis, platinum release and tumor growth 
inhibition mechanism of 2.1 
 
Figure 2-1: TEM micrographs of 2.1 
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Figure 2-2: Intensity(left) and number (right) weighted DLS spectra of 2.1 
Table 2-1:  Hydrodynamic diameters and zeta potential of various forms of 2.1 in PBS 
Particle ID Zavg (nm) PDI Intensity 
Average (nm) 
Number 
Average (nm) 
Zeta Potential 
(mV) 
2.1 77.8 ± 0.3 0.07 ± 0.01 84.5 ± 0.3 62.3 ± 0.2 -20.7 ±1.4 
Rhod-2.1 105.2 ± 0.5 0.09 ± 0.19 113.9 ± 0.8 90.3 ± 3 -21.8 ±1.1 
RGD-2.1 100.0±2.3 0.25± 0.05 102.9± 1.8 97.5±7.7 -18.2 
PEG-2.1 91.3±6.2 0.15± 0.03 95.2± 6.2 82.8±2.9 -5.5± 1.3 
APEG-2.1 92.6± 0.4 0.16 ± 0.05 94.8± 9.8 81.6±7.8 -5.0± 1.4 
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Figure 2-3:  TGA weight loss curve for 2.1. 
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Dye-doped particles of 2.1 (rhod-2.1) were obtained by incorporating a fraction of silyl-
derived rhodamine B into the microemulsion during the synthesis. Particles of rhod-2.1 had a 
similar size distribution as 1 (Figures 2-4 and 2-5, Table 2.-) but contained rhodamine B to 
facilitate confocal imaging studies. Rhod-2.1 had a slightly higher TGA weight loss as 
expected due to the incorporation of the organic dye (Figure 2-6) in the synthesis and also 
was fluorescent in the same wavelengths as the free dye (Figure 2-7). 
 
Figure 2-4: TEM micrographs of rhod-2.1 
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Figure 2-5:  Intensity (left) and number (right) weighted DLS spectra of 2.1 (black) and 
rhod-2.1 (cyan) in PBS. 
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Figure 2-6: TGA weight loss curves for 2.1 (black) and rhod-2.1 (cyan). 
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Figure 2-7:  Fluorescence spectra of rhod-2.1 as a dispersion in PBS. The excitation 
wavelength was 555 nm. 
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2.2.3 Platinum release from Nanoparticle 2.1 
We expect that 2.1 will be stable under normal physiological conditions, but the Pt(IV) 
prodrug in 2.1 can be rapidly reduced by endogenous biomolecules, such as glutathione and 
cysteine, to release (dach)PtCl2, which can then undergo hydrolysis (assisted by the low 
intracellular Cl- concentration) and DNA binding (Scheme 2.2). Release profile experiments 
revealed that 1 is stable in the absence of a reducing agent, with only 10% background 
release over 24 h (Figure 2.8). However, with the addition of 10 mM cysteine, ~30% of the 
platin cargo was quickly released, followed by a more gradual release of the cargo. ~80% of 
the payload was released after two days of incubation with cysteine.  When in circulation, 2.1 
would only encounter low concentrations of reducing agents (typically µM concentrations), 
so only a small amount of platinum would be released nonspecifically. However, the tumor 
microenvironment is generally highly reducing, so Pt(dach)Cl2 would be released locally to 
provide cancer chemotherapy. Also cellular endosomes have millimolar concentrations of 
reducing agents, so the platinum payload would also be released after endocytosis.  
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Figure 2.8: Platinum release profile from 2.1 in the absence and presence of 10mM L-
cysteine. The reducing agent was added where indicated by the arrow. 
 
2.2.4 Post-Synthetic Modification
 
Scheme 2.3: Post-synthetic modification strategies for 2.1 through either surface silanol 
groups (i) or carboxylic acids(ii).   
2.1 possesses two surface functional groups, silanol groups and carboxylic acids, which 
were used for post-synthesis grafting of cyclic arginine-glycine-aspartate (cRGD) peptide 
and polyethylene glycol (Scheme 2-3).  The surface silanol groups allow for the 
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functionalization of 2.1 with a variety of silanol derived molecules through traditional 
siloxane chemistry (Scheme 2-3, i).37-38 The carboxylic acids in 2.1 allows for the attachment 
of molecules through traditional coupling chemistry (Scheme 2-3, ii).39 2.1 was 
functionalized with silyl-derived cRGD by base-catalyzed condensation to afford RGD-2.1 
(Scheme 2-3, method i). The cRGD peptide targets the αvβ3 integrin, which is upregulated in 
many angiogenic tumor cells.40-42 DLS measurements showed an increase in particle size to 
100 nm, most likely due to slight particle aggregation after the peptide conjugation (Figure 2-
9, Table 2.1). The zeta potential slightly increased to -18.2 mV, consistent with the grafting 
of the neutral cRGD peptide (Table 2-1). 
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Figure 2-9: Intensity (left) and number (right) weighted DLS size distributions for 2.1 
(black) and RGD-2.1 (green) in PBS 
 
2.1 was also surface-modified with polyethylene glycol (PEG). PEG is an inert, nontoxic, 
and non-immunogenic hydrophilic polymer.43  Numerous studies of PEG-modified 
nanoparticles have demonstrated that the PEG coating sterically stabilizes the nanoparticle 
and imparts stealth properties such as prolonged circulation half-life, reduced serum protein 
binding, and avoidance of the mononuclear phagocytic system (MPS).5, 8, 12  Repeated 
attempts to pegylate 2.1 through surface silanol groups were unsuccessful, so PEG was 
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attached to the nanoparticle surface by an EDC-mediated coupling (EDC= 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide) between surface carboxylic acids on 2.1 and amino-
PEG2000-methyl ether (PEG-2.1). PEG-2.1 was characterized by TEM, DLS, zeta potential, 
and TGA. DLS measurements gave a hydrodynamic diameter of 91 nm for PEG-2.1, while 
the TEM micrograph showed minimal changes in the particle morphology (Figures 2-10 and 
2-11, Table 2-1). The zeta potential of PEG-2.1 increased to -5.5 mV (Table 2-1). This 
positive shift in the zeta potential to near neutral values is indicative of the formation of a 
dense PEG layer which shields the surface charge of the nanoparticles. A slight increase in 
the particle size was observed for PEG-2.1, probably resulting from the extension of the PEG 
chains from the nanoparticle surface. TGA analysis of PEG-2.1 gave an increase in organic 
weight loss of 8%, which corresponds to a coverage density of 1 PEG per 2.7 nm2 (Figure 2-
12). 
 
Figure 2-10: TEM micrographs of PEG-2.1. 
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Figure 2-11: Intensity (left) and number (right) weighted DLS spectra of 2.1 (black) and 
PEG-2.1 (blue) obtained in PBS. 
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Figure 2-12: TGA weight loss curves for 2.1 (black) and PEG-2.1 (blue) 
The anisamide (AA) ligand was also attached to the surface of 2.1 by an amide 
coupling between the carboxylic acid groups of 2.1 and amino-PEG2000-AA. The AA ligand 
is an effective targeting agent for the sigma receptor, an opioid receptor overexpressed on 
many cancers.44-49  AA-targeted PEG-2.1 (APEG-2.1) was prepared by the EDC coupling of 
2.1 with amino-PEG2000-methyl ether and amino-PEG2000-AA (in a 9:1 weight ratio) under 
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the same conditions as the above pegylation reaction.  TEM analysis demonstrated no change 
in particle size or morphology (Figure 2-13). APEG-2.1 particles exhibited a DLS diameter 
of 93 nm and a zeta potential of -5.0 mV (Figure 2-14 and Table 2-1). TGA showed an 
increase in organic weight loss of 8%, suggesting nearly identical PEG surface coverage in 
APEG-2.1 to that in PEG-2.1 (Figure 2-15). 
 
Figure 2-13: TEM micrographs of APEG-2.1 
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Figure 2-14: Intensity (left) and number (right) weighted DLS spectra of 2.1 (black), PEG-
2.1 (blue), and APEG-2.1 (red) obtained in PBS. 
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Figure 2-15: TGA weight loss curves for 2.1 (black), PEG-2.1 (blue) and APEG-2.1 (red) 
2.2.5 In Vitro Cytotoxicity Studies 
The cytotoxicity of 2.1 was evaluated in vitro against several human colon and pancreatic 
cancer lines, because oxaliplatin is used clinically to treat colon cancer and has been studied 
as a potential therapy for pancreatic cancer.50-52  Oxaliplatin, 2.1, and RGD-2.1 were 
evaluated against two colon adenocarcinoma cell lines: DLD-1 and HT-29 (Figures 2-16 and 
2-17). Against the DLD-1 cell line, oxaliplatin was highly effective, with an IC50 of 0.14 µM, 
while 2.1 had slightly better efficacy, with an IC50 of 0.11 µM. RGD-2.1 showed a 10-fold 
increase in cytotoxicity compared to both 2.1 and oxaliplatin, exhibiting an extremely low 
IC50 of 0.01 µM (Figure 2-16). Against the HT-29 cell line, oxaliplatin and 2.1 showed 
comparable cytotoxicity (IC50=0.175 and 0.145 µM, respectively), while RGD-2.1 was more 
than twice as cytotoxic (IC50=0.081 µM) (Figure 2-17). These results clearly indicate the 
ability to target particles of 2.1 to colon cancer cells with the cRGD ligand. 
59 
 
0 1 2
0
50
100
 
 
Pe
rc
en
t V
ia
bi
lit
y
[Pt] (μM)
 Oxaliplatin
 2.1
 RGD-2.1
 
Figure 2-16: Cell viability assays of oxaliplatin (red), 2.1 (black) and RGD-2.1 (blue) 
evaluated against DLD-1 human colon adenocarcinoma cells. 
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Figure 2-17: Cell viability assays of oxaliplatin (red), 2.1 (black) and RGD-2.1 (blue) 
evaluated against HT-29 human colon adenocarcinoma cells. 
 
Two pancreatic ductal adenocarcinoma cell lines, AsPC-1 and BxPC-3, were chosen to 
evaluate the cytotoxicity of 2.1, RGD-2.1, and oxaliplatin (Figures 2-18 and 2-19). Against 
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the AsPC-1 cell line, 2.1 and RGD-2.1 exhibited IC50 values of 0.75 and 0.6 µM, respectively 
(Figure 2-18). They were about three times as cytotoxic as oxaliplatin (IC50 = 2 µM). 
Oxaliplatin, 2.1, and RGD-2.1 showed comparable cytotoxicity against the BxPC-3 cell line, 
with an IC50 of 1, 0.8, and 1 µM, respectively (Figure 2-19). RGD-2.1 is not expected to 
show an increase in cytotoxicity compared to 2.1, as these cell lines do not express high 
levels of the αvβ3 integrin.53-54  Instead, we hypothesized that AA can be used to target AsPC-
1 cells which were shown previously to be sigma receptor positive.55  PEG-2.1 and 
oxaliplatin showed identical IC50 values of 0.52 and 0.37 µM, respectively (Figure 2-20), 
while anisamide targeting decreased the IC50 value of APEG-2.1 to 0.17 µM, equivalent to 
more than a 3-fold increase in cytotoxicity. 
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Figure 2-18: Cell viability assay of oxaliplatin (red), 2.1 (black), and RGD-2.1 (blue) 
evaluated against AsPC-1 pancreatic ductal adenocarcinoma cells. 
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Figure 2-19: Cell viability assay of oxaliplatin (red), 2.1 (black), and RGD-2.1 (blue) 
evaluated against BxPc-3 pancreatic ductal adenocarcinoma cells. 
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Figure 2-20: Cell viability assay of oxaliplatin (black), PEG-2.1 (blue) and APEG-2.1 (red) 
evaluated against AsPc-1 pancreatic ductal adenocarcinoma cells. 
2.2.6: In Vitro Confocal Microscopy Studies 
The in vitro cytotoxicity assay results clearly indicated the increased uptake of 2.1 by 
DLD-1 and HT-29 human colon cancer cells via integrin receptor targeting and by AsPC-1 
human pancreatic cancer cells via sigma receptor targeting, presumably through receptor-
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mediated endocytosis. The cellular localization and effect of RGD targeting of 2.1 was 
investigated by confocal microscopy. DLD-1 cells were incubated with either rhod-2.1 or 
RGD-rhod-2.1 for 10 minutes before being washed extensively to remove any unbound 
nanoparticles. This short reaction time was necessary because of the effectiveness of 2.1 in 
inducing apoptosis in DLD-1cells. Experiments using longer incubation times produced 
significant cell death, and few viable cells were located on the microscope slide.  DLD-1 
cells showed increased cellular localization and uptake of RGD-rhod-1 particles compared to 
the untargeted rhod-1 particles (Figure 2-21). The nanoparticles appear to be located in 
discrete areas within DLD-1 cells, most likely cellular endosomes.  
 
Figure 2.21: Overlaid confocal microscopy images of rhod-2.1 (top) and RGD-rhod-2.1 
(bottom) incubated with DLD-1 colon cancer cells at 0, 0.02, 0.05 and 0.1 mg nanoparticle 
per well. 
 
 The cellular localization, time dependence of internalization and induction of 
apoptosis by 2.1 was investigated in AsPC-1 cells by confocal microscopy (Figures 2-22 and 
Rhod‐
2.1 
RGD‐ 
Rhod‐
2.1 
0  mg 0.02 mg 0.05 mg 0.1 mg 
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2-23). Cells were treated with nanoparticle for either 1 hour or 5.5 hours at a fixed platinum 
concentration. The media was then removed and the cells were washed to remove any 
unbound nanoparticles. A FITC-Annexin V conjugate was then used to monitor cellular 
apoptosis.  Annexin V is a protein with a high affinity for the phospholipid 
phosphatidylserine. During apopotosis, phosphatidylserine becomes translocated from the 
inner cell membrane to the outer allowing for the detection of apopotosis.56  After 1 hour of 
incubation, no fluorescence was evident in the rhodamine B channel for cells incubated with 
rhod-2.1, but significant rhodamine B fluorescence was found for the cells incubated with 
PEG-rhod-2.1 and APEG-rhod-2.1 (Figure 2-22). Consistent with the efficient uptake of 
PEG-rhod-2.1 and APEG-rhod-2.1 particles, the FITC channels showed strong green 
fluorescence in both cases, indicating significant cell apoptosis induced by the released 
oxaliplatin from the endocytosed particles. In contrast, no apoptosis was observed for the 
cells incubated with no particles or rhod-2.1 particles. These results would suggest that the 
negatively charged rhod-2.1 nanoparticles cannot efficiently enter cells compared to the 
neutral pegylated nanoparticles. Additionally, these results confirm the triggered release 
capabilities of 2.1 as only internalized nanoparticles appear to be able to release their 
platinum payloads to cause apoptosis. Confocal images of the cells incubated for 5.5 hours 
with rhod-2.1 particles indicated a low level of particle uptake and cell apoptosis (much less 
than the cells that were treated with PEG-rhod-2.1 and APEG-rhod-2.1) (Figure 2-23). The 
confocal microscope imaging studies thus provided additional evidence for the enhanced 
uptake of PEG-rhod-2.1 and APEG-rhod-2.1 particles and triggered release of the platin 
cargoes in the AsPC-1 cells. The enhanced uptake of PEG-rhod-2.1 and APEG-rhod-2.1 was 
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surprising because pegylation would be expected to decrease cellular uptake; however, it is 
possible that these nanoparticles were insufficiently pegylated to reduce cell uptake.  
 
Figure 2-22: Laser scanning confocal microscopy images of AsPC-1 cells incubated with no 
particle, rhod-2.1, PEG-rhod-2.1, and APEG-rhod-2.1 for 1 hr (5µM Pt concentration) and 
then treated with Annexin V/FITC. The green fluorescence arises from FITC and the red 
fluorescence arises from rhodamine B. Scale bars= 50µm. 
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Figure 2-23: Laser scanning confocal microscopy images of AsPC-1 cells incubated with no 
particle, rhod-2.1, PEG-rhod-2.1, and APEG-rhod-2.1 for 5.5 hours at 5µM Pt. The cells 
were stained with FITC-Annexin V (green channel) to mark cellular apoptosis. Nanoparticle 
fluorescence is the red channel, and the scale bars indicate 50µm.  
2.2.7 In Vivo Studies 
 Encouraged by the promising in vitro results, we have evaluated the in vivo tumor 
growth inhibition efficacy of PEG-2.1 and APEG-2.1 against a murine model of pancreatic 
cancer. Female athymic nude mice were injected in both flanks with 1×106 AsPC-1 cells and 
the tumors grew until palpable in both flanks (typically 16-21 days after cell injection). The 
mice were randomly split into 4 groups (4-6 mice per group) and received three weekly doses 
of oxaliplatin (5 mg Pt/kg), PEG-1 (5 mg Pt/kg), APEG-1 (5 mg Pt/kg), or PBS control.  
These platinum doses are equivalent to the maximum tolerated dose of oxaliplatin for this 
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injection schedule.57 Figure 2-24 shows the effect of the treatments on tumor growth. Mice 
which received no treatment demonstrated sustained tumor growth, reaching the maximum 
size allowed by the UNC institutional animal care and use committee guidelines 21 days after 
the commencement of the treatment. Oxaliplatin appeared to slightly inhibit tumor growth 
over the study period (75% of the volume of untreated tumors), but the effect was not 
statistically significant. However, mice which received either PEG-1 or APEG-1 showed a 
statistically significant reduction in tumor growth (α =0.06 for PEG-1 and α=0.02 for APEG-
1), thus limiting the average tumor volume to approximately 50% and 40% of the volume for 
untreated control mice, respectively. Throughout the duration of the study, no weight loss 
was observed in any of the treatment groups (Figure 2-25). The antitumor efficacy of PEG-1 
and APEG-1 was confirmed by histological analysis of the resected tumors (Figures 2-26- 2-
29). Both the untreated and oxaliplatin-treated tumors were very large and composed of large 
regions of viable tumor cells (Figures 2-26- 2-29 a and b). The tumors from the oxaliplatin-
treated mice showed small necrotic regions around the center of the tumor mass. In contrast, 
mice which received PSQ nanoparticle treatment (Figures 2-26- 2-29 c and d) had smaller 
tumors composed of large regions of necrotic (scarred) tissue. Mice which received APEG-1 
showed much larger regions of necrotic tissue. These results suggest that PSQ nanoparticles 
are potentially useful therapies for the treatment of pancreatic cancer. 
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Figure 2-24: Tumor growth inhibition curves of oxaliplatin (green), PEG-2.1 (blue), APEG-
2.1 (red) and PBS control (black) administered by tail vein injection at 5mg Pt/kg on days 
0,7, and 14 against an AsPc-1 subcutaneous xenograft.  
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Figure 2-25: Mouse body weights of groups treated with oxaliplatin (green), PEG-2.1 (blue), 
APEG-2.1 (red) and PBS control (black) administered i.v. at 5mg Pt/kg. Treatment was 
administered on days 0, 7, and 14 against an AsPC-1 subcutaneous xenograft. Error bars are 
omitted for clarity. 
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Figure 2-26: Histology images of resected AsPc-1 tumors with H&E staining from mice 
receiving PBS control (a), oxaliplatin (b), PEG-2.1 (c), and APEG-2.1 (d). The scale bars 
indicated 0.5 mm. The blue-purple dots result from nuclear staining of viable cancer cells 
whereas the pinkish areas indicate necrotic tumor tissue with no viable cells or nuclear 
material.  
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Figure 2-27: AsPc-1 tumor histology images taken at 10x magnification for mice receiving 
PBS(A), oxaliplatin (B), PEG-2.1 (C), or APEG-2.1 (D). The blue purple dots result from 
viable cancer cells, the pink areas indicate regions of complete cellular necrosis, leaving no 
nuclear material to be stained purple and conversion of the area to an abscess and the white 
areas are regions of deposited fatty tissue. The scale bar indicates 500 µm. 
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Figure 2-28: AsPc-1 tumor histology images taken at 20x magnification for mice receiving 
PBS(A), oxaliplatin (B), PEG-2.1 (C), or APEG-2.1 (D). The blue purple dots result from 
viable cancer cells, the pink areas indicate regions of complete cellular necrosis, leaving no 
nuclear material to be stained purple and conversion of the area to an abscess and the white 
areas are regions of deposited fatty tissue. The scale bar indicates 120 µm. 
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Figure 2-29: AsPc-1 tumor histology images taken at 40x magnification for mice receiving 
PBS(A), oxaliplatin (B), PEG-2.1 (C), or APEG-2.1 (D). The blue purple dots result from 
viable cancer cells, the pink areas indicate regions of complete cellular necrosis, leaving no 
nuclear material to be stained purple and conversion of the area to an abscess and the white 
areas are regions of deposited fatty tissue. The scale bar indicates 60 µm. 
 PEG-2.1 was further evaluated against an orthotopic model of pancreatic cancer. In 
an orthotopic model, the cancer cells are implanted within their derived organ instead of the 
flanks of the mouse. Orthotopic models mimic the natural organ microenvironment of the 
human cancer cells. This can influence the tumor’s growth characteristics, metastatic 
potential, and response to chemotherapy.58 Luciferase expressing AsPC-1 cells were 
orthotopically implanted (i.e., injected into the pancreas in this case) within nu/nu mice and 
the tumors were allowed to grow until detected by fluorescent imaging. Mice were then split 
into 3 groups (5 mice per group) and received PBS control, oxaliplatin or PEG-2.1at 5mg 
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Pt/kg for three weekly doses. APEG-2.1 was not included in this study due to both mouse 
availability only allowing three treatment groups for statistically significant results and the 
modest increase in efficacy brought upon by anisamide targeting. The mice were injected 
with luciferin weekly and imaged. Tumor growth was determined by the relative increase in 
fluorescence compared to the day-1 fluorescence. As seen in figure 2-30, the fluorescence 
intensity of mice receiving no treatment increased nearly 3 times over the course of the study.  
Oxaliplatin appeared to have had no tumor growth inhibition effect, while administration of 
PEG-2.1 seemed to only result in a modest increase in tumor volume (29%). However, the 
error within the measurements was too large to achieve any statically significant results. This 
study was terminated early due to technical issues arising from repeated injections so long 
term tumor growth or survival data was not obtained.  
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Figure 2-30: Luminescence intensity increases of mice orthotopically implanted with 
luciferase expressing AsPc-1 tumors and receiving either PBS (black), oxaliplatin (green), or 
PEG-2.1 (blue) via tail vein injection at 5mg Pt/kg. The study was terminated prematurely 
due to adverse effects from repeated tail vein injection. 
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2.3 Conclusions 
In conclusion, we have synthesized PSQ nanoparticles containing extremely high 
loadings of oxaliplatin-based chemotherapeutics. These nanoparticles are highly stable under 
normal physiological conditions, but can be readily reduced to release the platin cargoes in 
highly reducing tumor microenvironments. The Pt(IV) centers within the PSQ nanoparticle 
would allow the cargo to remain inside of cancer cells in circulation, but could be reduced 
inside of the tumor environment. The PSQ particles contained both surface silanol and 
carboxylic acid groups to allow further functionalization with PEG and targeting ligands. The 
PSQ particles exhibited superior cytotoxicity to oxaliplatin against four cancer cell lines in 
vitro, and the RGD- and anisamide-targeting further enhanced the cytotoxicity. In a 
pancreatic cancer xenograft mouse model, the pegylated and anisamide-targeted PSQ 
particles showed drastically superior efficacy to oxaliplatin in inhibiting tumor growth. These 
results were tentatively extended to an orthotopic model of pancreatic cancer. This work 
highlights the potential of PSQ nanoparticles as excellent delivery vehicles for cancer 
therapeutics. 
2.4 Materials and Methods 
2.4.1 General Materials and Methods 
 All chemicals were purchased from Fisher or Aldrich and used without further 
purification unless noted.  Oxaliplatin was purchased from AK scientific. Tetrahydrofuran 
was dried by the sodium metal/benzophenone method.  Thermogravimetric analysis was 
performed using a Shimadzu TGA-50 equipped with a platinum pan and heated at 3°C per 
minute in air. A JEM 100CX-2 transmission electron microscope (TEM) was used to 
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determine particle size and morphology. TEM samples were prepared from ethanolic 
suspensions of the nanoparticles dropped onto amorphous carbon coated copper grids. The 
solvent was then allowed to evaporate. Dynamic light scattering (DLS) and zeta potential 
measurements were made using a Malvern Instruments Zetasizer Nano.  Inductively-Coupled 
Plasma Mass Spectrometry (ICP-MS) measurements were made using a Varian 820-MS 
Inductively-Coupled Plasma Mass Spectrometer. ICP-MS samples were prepared by 
digesting a known amount of sample in concentrated nitric acid overnight, and then diluted 
with water to 2% nitric acid by volume.  
2.4.2 Synthesis of Platinum Complexes 
Synthesis of Pt(dach)Cl2: Pt(dach)Cl2 was synthesized using Dhara’s method.27 K2PtCl4 (2.07 
g, .005 mol) was dissolved in 60 mL of H2O and allowed to stir for 10 min.  KI (3.20 g, .019 
mol, 3.8 eq) was dissolved in 10 mL of H2O and added to the mixture, resulting in a violet 
solution that was stirred for 15 min. R,R-diaminocyclohexane (dach) (591.5 mg, 0.0052 mol, 
1 eq) was dissolved in 10 mL of H2O and added to the mixture dropwise, resulting in the 
yellow Pt(dach)I2 precipitate, which was stirred overnight, at room temperature, in the dark. 
Pt(dach)I2 was filtered by vacuum and washed with H2O, acetone, and ethanol (2.71 g, .0047 
mol, 95% yield).  Pt(dach)I2 was suspended in 60 mL of H2O, and AgNO3 (1.71 g, .010 mol, 
2 eq) dissolved in 10 mL H2O was added to the slurry and stirred for 24 h at room 
temperature. The AgI precipitate was removed by vacuum filtration, and a saturated NaCl 
solution was added dropwise until the yellow Pt(dach)Cl2 precipitated and was filtered and 
washed with H2O, EtOH, and acetone. Yield = 95%. IR spectra (3320, 3200, 2960, 2880 cm-
1) 
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Synthesis of Pt(dach)Cl2(OH)2: Pt(dach)Cl2(OH)2 was synthesized by a modification of a 
previously reported procedure.28 Pt(dach)Cl2 (1.48 g, .0039 mol) was suspended in 60 mL 
H2O, followed by the addition of 14 mL of 30% H2O2 in water. The slurry was heated at 70 
°C overnight, in the dark. The white product was filtered and washed with H2O and acetone. 
Yield = 68%. 
Synthesis of c,c,t-Pt(dach)Cl2(propyltriethoxysilane succinic acid)2 (DachPt-Si): c,c,t-
Pt(Dach)Cl2(OH)2 (0.2 g, .0004 mol) was dried under vacuum for several hours. The Pt 
complex was then suspended in 6 mL of anhydrous DMSO and triethoxysilylpropyl succinic 
anhydride (600 µL, 0.002 mol, 4 eq) was added. The mixture was heated under argon at 50 
°C for 4 days, yielding a brown solution. The solvent was removed by lyophilization. The 
residue was dissolved in ethanol and precipitated with hexane. The brown solid was washed 
twice with diethyl ether and dried under vacuum for several hours. Yield: 247 mg, 50%. 1H 
NMR (400 MHz, DMSO-d6): δ 12.22 (2 H, COOH), 8.19 (4H, NH2), 4.041 (4H, Si-OH), 
3.737 (4H, Si-OCH2), 3.07 (2H), 2.33 (2H), 2.19 (2H), 1.501 (8H), 1.375 (8H), 1.15 (6H), 
0.582 (4H).   
2.4.3 Synthesis of Silyl-Derived Molecules 
Synthesis of Rhodamine-APS: Rhodamine B-APS was synthesized by an established 
procedure.59  Rhodamine B (6.8 mg, 1.4x10-5 mol) was dissolved into 1.1 mL of absolute 
ethanol. 3-aminopropyltriethoxysilane (3.3 µL, 1.4x10-5 mol) was added and the reaction was 
stirred under nitrogen for 24 h at room temperature, in the dark. The solution was then 
diluted to a total volume of 2 mL with additional ethanol to make a 6 mM solution. 
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Synthesis of triethoxysilylpropyl carbomoyl c(RGDfK): Triethoxysiylpropyl carbomoyl 
c(RGDfK) was synthesized by an established method.13  Cyclic(RGDfK) (2.0 mg, 3.3 μmol) 
was added to a small round-bottom flask and dried under high vacuum for 1 h. Anhydrous 
DMSO (500 μL) and triethylamine (0.20 μL) were added to the round-bottom flask, followed 
by (3-isocyanatopropyl)triethoxysilane (0.86 μL, 3.44 μmol). The mixture was magnetically 
stirred under argon for 24 h. The solution (4 mg c(RGDfK)/mL DMSO) was placed in a 
freezer for later use. 
2.4.4: Synthesis of Polyethylene Glycol (MW=2000) Derivatives 
Synthesis of MeO-PEG2000-NH2: Methoxy-PEG2000 –amino was synthesized by a 
modification of a previously reported protocol.60  Peg2000 monomethylether (10 g, 5.0 mmol) 
was co-evaporated with 50 mL of toluene to remove water.  The PEG was dissolved into 50 
mL of anhydrous THF with 1.2 mL (15.5 mmol) of methane sulfonyl chloride. The solution 
was cooled to 0°C on an ice bath, then 2.3 mL (16.5 mmol) of triethylamine dissolved in 20 
mL THF was added dropwise. The solution was stirred from 0°C to room temperature 
overnight. Water (50 mL) was added and the solution was cooled back to 0°C.  Sodium 
bicarbonate solution (5 mL, 1 M) was added, followed by sodium azide (1.3 g, 20 mmol).  
The THF was removed by rotary evaporation. The remaining aqueous solution was refluxed 
for 24 h. The PEG was extracted with dichloromethane (4×100 mL). The DCM layers were 
collected, concentrated, and extracted once with brine.  The dichloromethane was then 
removed by rotary evaporation, yielding solid methoxy-PEG2000-azide (8.9 g, 89% yield).  
The methoxy-PEG2000-azide was dissolved into 55 mL THF and triphenylphosphine (3.42 g, 
13 mmol) was added. The solution was stirred for 10 h at room temperature, and then water 
(3.3 mL) was added. The solution was stirred at room temperature overnight, and then the 
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THF was removed by rotary evaporation.  Water (100 mL) was added to precipitate 
triphenylphosphine oxide, which was then removed by filtration. The water was removed by 
rotary evaporation. Yield: 6 g (60% vs. Peg2000 monomethylether). 1H NMR: (400MHz, 
CDCl3) 3.615 (180 H), 3.43 (2H), 3.35 (3H). 
Synthesis of Anisamide-PEG2000-NH2: DiaminoPEG2000 was synthesized by a previously 
reported method.60 DiaminoPEG2000 (2 g, 1 mmol) were dissolved into 100 mL of 
dichoromethane. Subsequently, 4-methoxybenzoic acid (182.4 mg, 1.1 eq), 
dicyclohexylcarbodiimide (308 mg, 1.5 mmol) and 4-dimethyl-aminopyridine (140 mg, 1.1 
mmol) were dissolved into the PEG solution. The solution was stirred at room temperature 
for 24 h, and then the dicyclohexylurea byproduct was removed by filtration. The 
dichloromethane was removed by rotary evaporation. The desired anisamide-PEG2000-NH2 
product was isolated by silica gel chromatography using 10% MeOH in CH2Cl2.  Yield: 700 
mg, 33%.  1H NMR (400MHz, CDCl3), 7.767 (2H), 6.891 (2H), 3.82 (2H), 3.61 (180H), 3.44 
(2H)   
2.4.5: Nanoparticle Synthesis 
Synthesis of Pt(Dach)-based polysilsesquioxane nanoparticles (2.1): DachPt-Si (30 mg, 
2.9x10-5 mol) was dissolved in 3.25 mL ammonium hydroxide (33%) aqueous solution and 
then added to 125 mL of a 0.3 M AOT solution in hexanes. The microemulsion was stirred 
for 10 min, until it became optically transparent. An additional 500 µL of ammonium 
hydroxide was added. The microemulsion was stirred for 24 h, in the dark. An equal volume 
of ethanol was added to quench the reaction and precipitate the nanoparticles. The particles 
were isolated by centrifugation and washed three times with ethanol. The particles were 
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stored as an ethanolic suspension. The nanoparticles were characterized by DLS, TEM, TGA 
and ICP-MS.   
Synthesis of rhodamine-tagged nanoparticles (Rhod-2.1): DachPt-Si (12 mg,  1.1x10-5 mol) 
was dissolved in 1.3 mL ammonium hydroxide (33%), and then added to 50 mL of a 0.3 M 
AOT solution in hexanes. Rhodamine-APS solution (100 µL, 5.8x10-7 mol) was added. The 
microemulsion was stirred for 10 min, until optically transparent. An additional 200 µL of 
ammonium hydroxide was added. The microemulsion was stirred for 24 h. An equal volume 
of ethanol was added to quench the reaction and the particles were isolated by centrifugation 
and washed twice with ethanol. All subsequent post-synthetic modification of rhod-2.1 
followed the same procedures listed below for 2.1. 
2.4.6: Nanoparticle Surface Functionalization 
Conjugation of triethoxysilylpropyl carbomoyl c(RGDfK) to 2.1 (RGD-2.1): 2.1 was 
dispersed in ethanol at a concentration of 2mg/mL. Tri(ethoxy)silylpropyl carbomoyl 
c(RGDfK) solution was added (5% by mass). The pH of the solution was adjusted to 10 with 
aqueous ammonium hydroxide, and the resulting suspension was stirred for 24 h, in the dark. 
The particles were isolated by centrifugation and washed twice with ethanol. The resulting 
particles were analyzed by DLS and zeta potential. 
Pegylation of 2.1 (PEG-2.1): 2.1 was redispersed into an acetonitrile solution containing 7 
mM EDC and Peg2000-NH2 (1.65 mM) at 2mg/mL. The suspension was stirred at 50°C for 
24 h, in the dark. The particles were isolated by centrifugation and washed twice with 
ethanol. The particles were analyzed by DLS and zeta potential. 
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Synthesis of anisamide-targeted-Pegylated 2.1 (APEG-2.1): 2.1 was re-dispersed at 2mg/mL 
into an acetonitrile solution containing 7 mM EDC, 0.165 mM anisamide-PEG2000-NH2, and 
1.65 mM PEG2000-NH2. The suspension was stirred at 50°C for 24 h, in the dark. The 
particles were isolated by centrifugation and washed twice with ethanol. The particles were 
analyzed by DLS and zeta potential. 
2.4.7 Platinum Release from 2.1 
Two milligrams of 2.1 were redispersed into 1 mL 2 mM HEPES buffer (pH=7.4).  The 
nanoparticle suspension was placed into a 3500 MW cutoff dialysis bag, and the bag was 
placed into 360 mL 2 mM HEPES buffer at 37°C. The solution was sparged with argon and 
sealed within an air-free apparatus. The solution was incubated at 37°C for 22.5 h, with 
dialysate aliquots removed periodically. L-cysteine was added in deoxygenated HEPES for a 
total concentration of 5mM. The dialysate was incubated at 37°C, with aliquots removed 
periodically. Platinum release was determined by ICP-MS. 
2.4.8 In Vitro Assays 
General: DLD-1 human colorectal adenocarcinoma cells (ATCC# CCL-221) and HT-29 
human colorectal adenocarcinoma cells (ATCC# HTB-38) were purchased from the Tissue 
Culture Facility of the Lineberger Comprehensive Cancer Center at the University of North 
Carolina at Chapel Hill. DLD-1 cells were cultured in RPMI-1640 growth medium (Cellgro) 
supplemented with 10% fetal bovine serum (Sigma) and 2% pencillin-streptomycin (Sigma). 
HT-29 cells were cultured in McCoys 5A 1X growth medium (Mediatech) supplemented 
with 10%FBS (Mediatech) and 2% penicillin-streptomycin solution. AsPC-1 human 
pancreatic adenocarcinoma cells (ATCC# CRL-1682) and BxPC-3 human pancreatic 
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adenocarcinoma cells (ATCC# CRL-1687) were received from the laboratory of Dr. Jen Jen 
Yeh at the University of North Carolina at Chapel Hill. AsPC-1 and BxPC-3 cells were 
cultured in RPMI-1640 growth medium supplemented with 10% FBS and 2% pencillin-
streptomycin.  
DLD-1 Colon cancer cell viability assay: Confluent DLD-1 cells were trypsinized and 
counted with a hematocytometer. Cells were plated in 6-well plates at a cell density of 
50,000 cells/well and 3 mL of complete growth medium. Plates were incubated at 37°C, 5% 
CO2, overnight. Media was removed from wells, and each well was washed with 2 mL of 
PBS. Drug/particle solutions were prepared in media containing 5% PBS. Aliquots of 
drug/particle solutions and media (5% PBS) were given to each well to result in drug/particle 
concentrations of 0, 0.025, 0.25, 0.5, 1, and 2 µM. Plates were incubated for 3 days, and 
viability was determined via the trypan blue exclusion assay. 
HT-29 colon cancer cell cell viability assay: HT-29 cells were plated in 6-well plates in 3 mL 
of media at a cell density of 100,000cells/well, and were incubated for 12 h to promote cell 
attachment. Media was removed from the wells and each well was washed with 2 mL PBS. 5 
µM drug stock solutions were prepared with oxaliplatin, 2.1, and RGD-2.1, and these were 
added to wells, along with additional media, resulting in concentrations of 0, 0.1, 0.25, 0.5, 1 
and 5 µM.  The plates were incubated for 48 h, and cell viability was determined using the 
trypan blue exclusion assay. 
BxPc-3 pancreatic cancer cell viability assay: Confluent BxPC-3 cells were trypsinized and 
counted using a hemocytometer. Cells were plated in 6-well plates at a cell density of 
100,000 cells/well and 3 mL of complete growth medium. Plates were incubated at 37°C, 5% 
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CO2, overnight. Media was removed from wells, and each well was washed with 2 mL PBS. 
Drug/particle solutions were prepared in media containing 5% PBS. Aliquots of drug/particle 
solutions and media (5% PBS) were distributed to each well, resulting in drug/particle 
concentrations of 0, 1, 2.5, 6, 12.5, and 25 µM. Plates were incubated for 3 days, and 
viability was determined using the trypan blue exclusion assay. 
AsPC-1 pancreatic cancer cell viability assay: Confluent AsPC-1 cells were trypsinized and 
counted using a hemocytometer. Cells were plated in 6-well plates at a cell density of 
100,000 cells/well and 2 mL of complete growth medium. Plates were incubated at 37°C, 5% 
CO2, overnight. Media was removed from wells, and each well was washed with 2 mL PBS. 
Drug/particle solutions were prepared in media containing 5% PBS. Aliquots of drug/particle 
solutions and media (5% PBS) were given to each well, resulting in drug/particle 
concentrations of 0, 1, 2.5, 6, 12.5, and 25 µM. Plates were incubated for 3 days, and 
viability was determined via the trypan blue exclusion assay. 
Confocal Microscopy-DLD-1 cancer cells: Glass microscope coverslips were silanized by a 
reported protocol.61 Confluent DLD-1 cells were trypsinized and counted using a 
hemocytometer. Cells were plated in 6-well plates containing coverslips at a cell density of 
300,000 cells/well and 3 mL of complete growth medium. Plates were incubated at 37°C, 5% 
CO2, overnight. Media was removed from the plates and each well was washed with 2 mL 
PBS. Particle dispersions were prepared in PBS. Wells were given aliquots of particle 
dispersion, PBS, and media to yield concentrations of 0, 0.02, 0.05, and 0.1 mg/well. Wells 
were incubated at 37°C, 5% CO2, for 10 minutes. The media was removed, each well washed 
with 2 mL PBS, and 1 mL fresh media added to each well. The coverslips were adhered on 
slides and imaged on a Zeiss Pascal laser scanning confocal microscope at the Microscopy 
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Services Laboratory of the Department of Pathology and Laboratory Medicine at UNC-
Chapel Hill. 
Confocal Microscopy AsPC-1 pancreatic cells: Glass coverslips were silanized by a 
previously reported protocol61 and placed within the wells of a 6-well plate. AsPC-1 cells 
were collected by trypsinization and counted using a hemocytometer. Cells were plated at a 
cell density of 250,000 cells/well (3 mL media). The plates were incubated at 37°C, 5% CO2, 
overnight to promote cell adhesion. The media was removed, and the wells were washed 
twice with 1 mL PBS. The plates were refilled with media (2 mL) containing rhod-2.1, PEG-
rhod-2.1, or APEG-rhod-2.1 at a Pt concentration of 5 µM or no nanoparticle (as a control). 
The plates were incubated for either 1 or 5.5 hours. After the incubation period, the media 
was removed, and each well was washed with 1 mL PBS. The wells were refilled with 1 mL 
media containing 15 µL FITC-Annexin V (Invitrogen). The plates were incubated for 15 
min, the media was removed, and each well was washed with 1 mL PBS.  The coverslips 
were removed from each well and the cells were mounted onto glass slides. Cells were 
imaged at the Microscopy Services Laboratory at the University of North Carolina at Chapel 
Hill on an Olympus FV500 laser scanning confocal microscope.  
2.4.9 In Vivo Assays 
AsPC-1 subcutaneous mouse xenografts: Female athymic nude mice (6-8 weeks old) were 
purchased from Jackson Laboratories. Mice were cared for according to an approved 
protocol by the institutional animal care and use committee. AsPC-1 cells were suspended in 
50% matrigel (BD Biosciences) and 50% RPMI-1640 medium at 1,000,000 cells/mL. The 
cells were injected subcutaneously in both flanks with 100 µL of the cell suspension. Tumor 
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growth was measured every Monday, Wednesday, and Friday, and treatment commenced 
when tumors were palpable in each flank. Treatments were administered by tail vein 
injection with 100 µL PBS. The mice were divided into 4 groups (4-6 mice per group) and 
received PBS (control), oxaliplatin (5 mg Pt/kg), PEG-1 (5mg Pt/kg) or APEG-1 (5 mg 
Pt/kg)  The mice received treatments once a week for three weeks (days 0, 7, and 14).  
Tumor volume was calculated by the formula (a x b x c)/2, where a, b, and c are the tumor 
dimensions in three directions.  Tumor growth was monitored every Monday, Wednesday, 
and Friday until the tumor size reached the maximum allowed size. Mice weights were 
recorded weekly throughout the study. The mice were euthanized by CO2 inhalation and 
cervical dislocation. The tumors were then removed and fixed in formalin. 
AsPc-1 orthotopic pancreatic cancer model: AsPC-1-luciferase cells were orthotopically 
implanted within the pancreas of nu/nu mice (100,000 cells) and the tumors were allowed to 
grow until detected by optical imaging. Mice were injected with either oxaliplatin (5mg Pt), 
PEG-2.1 (5mg Pt/kg), or PBS control through the tail vein (100µL total volume) on study 
days 0, 7, 14, and 21. Tumor growth was monitored weekly by luciferin injections (100µL) 
and imaged post-injection on a IVIS-100 system. The data was analyzed using Xenogen 
Living Image software by analyzing the total luminescent counts and normalizing against the 
background image. Luminescence intensities were normalized compared to the day -1 
luminescence intensity.    
2.4.10 Ex Vivo Tissue Histology 
Tumors were received in a formalin solution.  For histology, the tumors were placed 
in labeled cassettes and flushed with water for 20 min. The tumors were then transported to 
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the Lineberger Comprehensive Cancer Center Animal Histopathology Core Lab in a 70% 
ethanol solution where they were pariffinized, cut, and H&E stained.  The stained tumors 
were imaged at the UNC Microscopy Services Laboratory using an Olympus BX61 Upright 
Fluorescence Microscope equipped with Improvision’s Volocity software. Images were 
captured using a QImaging RETIGA 4000R color camera.  
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Chapter 3: Co-condensed Silica Nanoparticles for Platinum-based Anticancer Drug 
Delivery 
 
3.1 Introduction 
 Since its discovery in 1960 by Rosenberg and coworkers, cisplatin has played a major 
role in cancer chemotherapy.1 Cisplatin is clinically used against a variety of different 
cancers such as testicular, breast, lung, cervical, head and neck, and ovarian cancers.2-6 It is 
one of the most widely used and potent cancer chemotherapies, but cisplatin chemotherapy is 
limited by its high general toxicity and severe side effects. Some cancers also display 
inherent or acquired resistance to cisplatin therapy.7-8 Despite an intense research effort of 
screening thousands of platinum compounds in the past few decades, only two additional 
platinum complexes, carboplatin and oxaliplatin, have been approved by the FDA.9 There 
exists an acute need to develop strategies to effectively deliver platinum drugs to the tumor 
while limiting side effects. 
 Nanomaterials offer a potential solution.  Nanoparticle therapeutics generally have a 
superior biodistribution over small molecule therapies due to longer circulation times. 
Resulting from their size, nanomaterials cannot penetrate normal vasculatures and capillaries, 
leading to a lower nanoparticle effective dose to healthy organs such as the skin, muscle, 
lungs and heart compared to small molecules, which would reduce side effects. 
Nanomaterials also have higher tumor uptake, due to the enhanced permeability and retention 
92 
 
effect, and tumor uptake can be enhanced with the conjugation of targeting ligands to the 
nanoparticle surface.10 Nanoparticulate therapeutic agents offer tailorable size, surface 
properties, and drug release rates which would allow for the optimization of nanoparticle 
efficacy.11-13  Our lab has recently developed two nanoscale coordination polymers (NCPs) 
as potential delivery vectors for cisplatin therapy.14-15 These materials demonstrated high 
drug loading and comparable cytotoxicity to cisplatin in vitro; however, NCPs readily 
degrade under physiological conditions, limiting their in vivo utility. We sought to develop a 
more stable nanoparticle platform for cisplatin delivery, which would be stable under normal 
physiological conditions. The drug can be triggered to be released from the nanoparticles 
once they reach the tumor microenvironment.   
 Silica-based nanomaterials have received an increasing amount of attention for 
biomedical applications.16-22 Silica is an inert, biocompatible matrix material that can be 
functionalized by a variety of covalent and non-covalent strategies.16, 21, 23-25 Our lab has 
developed several solid or mesoporous silica nanoparticle platforms for magnetic resonance 
and optical imaging.26-30  A silica-based material, known as Cornell dots (C-dots), is 
undergoing clinical investigation as an optical contrast agent.31 This chapter reports the 
development of hybrid silica nanospheres for cisplatin delivery. The development of these 
silica nanoparticles begins with the synthesis of a platinum(IV) cisplatin prodrug. The 
prodrug is incorporated covalently into a silica nanoparticle by co-condensation of the silica 
and platinum precursors. The silica nanoparticles can be post-synthetically modified to 
include a cancer-targeting peptide and are evaluated in vitro against human non-small cell 
lung cancer cell lines.  
 
93 
 
3.2 Results and Discussion 
3.2.1 Platinum Complex Synthesis 
 The platinum(IV) complex c,c,t-Pt(NH3)2Cl2(triethoxysilylpropyl succinate)2 (DSCP-
Si) was synthesized from commercially available cisplatin (Scheme 3-1). Cisplatin was 
oxidized using hydrogen peroxide in water to form c,c,t-Pt(NH3)2Cl2(OH)2 in good yields 
(typically around 75%) (Scheme 3.1, i). The hydroxyl groups in c,c,t-Pt(NH3)2Cl2(OH)2 act 
as nucleophiles and react with electrophilic groups, 32-33 in this case, the carbonyl groups of 
triethoxysilylpropyl succinic anhydride, to form DSCP-Si at a 78% yield (Scheme 3-1, ii). 
This platinum complex has two orthogonal functional groups: triethoxysilyl groups to allow 
for covalent attachment within the silica matrix and carboxylic acids to allow for post-
synthetic modification of the synthesized nanoparticles.  
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Scheme 3-1: Schematic of the synthesis of the platinum complexes used i) cisplatin is 
oxidized with hydrogen peroxide in water to form c,c,t-Pt(NH3)2Cl2(OH)2. ii) c,c,t-
Pt(NH3)2Cl2(OH)2 reacts with triethoxysilyl propyl succinic anhydride to form DSCP-Si. 
 
3.2.2: Synthesis of Co-condensed Silica Nanoparticles  
 A water-in-oil, or reverse, microemulsion was used to synthesize the silica 
nanoparticles with DSCP-Si and tetraethylorthosilicate (TEOS) as the silica source. Reverse 
microemulsions are a common way to synthesize silica nanoparticles with diameters under 
50 nm and have been used by our group, and others, to synthesize a variety of functional, 
monodisperse silica nanoparticles of different sizes.16, 23, 28, 34-35 To synthesize silica 
nanoparticles with co-condensed platinum complexes, we employed a reverse microemulsion 
based on the neutral surfactant Triton X100, with 1-hexanol as the co-surfactant and 
cyclohexanes as the oil phase. DSCP-Si was dissolved into the water phase and added to the 
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oil phase to create the microemulsion (Scheme 3-2). TEOS was then added to the reaction 
mixture, followed by ammonium hydroxide. Hydrophobic TEOS molecules remain in the oil 
phase of the microemulsion, diffusing to the oil-water interface. TEOS is hydrolyzed, 
entering the water phase. Subsequent condensation of orthosilicic acid and DSCP-Si affords 
the co-condensed silica nanoparticles (Scheme 3-2). The reaction is quenched by the addition 
of an equal volume of ethanol and the particles are isolated by centrifugation.  
 
Scheme 3-2: Schematic demonstrating the synthesis of co-condensed silica nanoparticles. 
TEOS diffuses into the water droplets and subsequent hydrolysis and condensation leads to 
the creation of the Pt-containing nanoparticles within the water droplets. 
 Nanoparticles 3.1, 3.2, 3.3, and 3.4 were synthesized within a 0.3 M Triton X100 and 
1.5 M 1-hexanol in cyclohexanes reverse microemulsion using ammonia as a base catalyst. 
The W value (water to surfactant molar ratio) of this microemulsion was 7.5. Particles 3.1, 
3.2, 3.3, and 3.4 correspond to the molar equivalents of TEOS of 5, 10, 15, and 20, 
respectively.  Ethanol was added after 3 hours after the initiation of the particle synthesis to 
quench the reaction; the particles were isolated by centrifugation and washed with ethanol to 
remove any residual surfactants. SEM images of the as-synthesized nanoparticles showed a 
change in nanoparticle morphology as a result of the different amount of TEOS added to the 
microemulsion (Figure 3-1). 3.1 had a fused and fiber-like morphology with no clearly-
defined individual nanoparticles (Figure 3-1 A).  Nanoparticles with 10 equivalents of TEOS 
(3.2) were spherical and approximately 50-75 nm in diameter. There was some degrees of 
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polydispersity, as there were a few larger nanoparticles present (Figure 3-1 B). 3.3 was in the 
same size regime, with some larger fiber-like nanoparticles present (Figure 3-1 C). 3.4 
yielded smaller nanoparticles that were approximately 30 nm in diameter (Figure 3-1 D). 
Dynamic light scattering (DLS) measurements of 3.2, 3.3, and 3.4 in 5 mM PBS (pH= 7.4) 
demonstrated that all three nanoparticles had multimodal intensity distributions (Figure 3-2, 
Table 3-1). This is due to the presence of a small amount of larger nanoparticles, which could 
not be completely removed from the synthesis and/or salt-induced aggregation of the 
nanoparticles. However, the number-weighted distribution data of all three nanoparticles was 
unimodal and corresponded roughly to the SEM diameter (Figure 3-2, Table 3-1). 
Inductively-coupled plasma-mass spectrometry (ICP-MS) measurements of 3.2-3.4 
demonstrated a modest cisplatin loading of 9.2-18.4 wt%; however, the thermogravimetric 
analysis (TGA) weight loss curves gave much higher organic weight loss than expected, due 
to incompletely hydrolyzed silica species within the nanoparticle (Figure 3-3). This 
hypothesis was supported by TGA analysis of pure silica nanoparticles synthesized under the 
same conditions, which had considerable organic weight loss.  
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Figure 3-1: SEM images of as synthesized 3.1 (A), 3.2 (B), 3.3 (C), and 3.4 (D). 
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Figure 3-2: Intensity (left) and number (right) weighted DLS spectra of 3.2 (red), 3.3 (blue) 
and 3.4 (black) obtained in PBS. 
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Table 3-1: Hydrodynamic diameters of different forms of nanoparticles obtained in PBS. 
The numbers in parentheses are the average percent volumes for multimodal size 
distributions. All measurements are the average of 3 independent measurements. N.A.= not 
available 
Particle ID Zavg (nm) PDI Intensity Average 
(nm) 
Number 
Average (nm) 
Zeta Potential 
(mV) 
3.2 185 ± 5 .39 ± 0.01 248± 12 (85) 
39 ± 5 (11)  
5178± 98 (4) 
29 ± 3 N.A 
3.3 136 ± 44 0.47 ± .06 200 ± 44 (74)
 39± 8 (25) 
4964 (1) 
30 ± 1.5 N.A 
3.4 114 ± 5 0.44± 0.04 199 ± 22 (86) 
34 ± 2 (13) 
5020 (1) 
24 ± 2 N.A.
3.5 108 ± 1 0.33 ± .01 142 ± 33 (92)
682 (5) 
4849± 33 (3) 
54 ± 4 -25.1 ± 1.1
3.6 193 ± 0.3 0.12 ± .12 221 ± 1 137 ± 3 -29.75 ± 0.5
RGD-3.6 222 ± 3 0.17 ± 0.03 243 ± 15 166 ± 0.3 -21.1 ±  0.4
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Figure 3-3: TGA weight loss curves for silica nanoparticles synthesized under the same 
reaction conditions TEOS only (black), 3.1 (red), 3.2 (green), 3.3 (blue) and 3.4 (maroon). 
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 In order to increase the extent of silanol condensation, the reaction time was extended 
to 24 hours. The nanoparticles 3.5 and 3.6 were synthesized by the same reverse 
microemuslion method described above with 5 and 10 molar equivalents of TEOS, 
respectively. Additionally, we expected that these nanoparticles would be slightly larger than 
those synthesized in three hours, owing to the increased particle growth. SEM images of 3.5 
and 3.6 showed well-defined spherical nanoparticles of 40-100 nm and 75-100 nm in 
diameter, respectively (Figure 3-4). TEM and HRTEM images of 3.5 and 3.6 confirmed the 
SEM size measurements and distributions. Additionally, the internal structure of 3.5 and 3.6 
could be probed by TEM; both nanoparticles possessed a solid, uniform structure which 
confirms that the DSCP-Si is homogeneously distributed throughout the nanoparticle interior 
(Figures 3-5 and 3-6). Under physiological conditions, 3.5 is 108 nm in diameter (Table 3-1, 
Figure 3-7) due to slight aggregation of the nanoparticles, evidenced by both the intensity-
weighted size distribution (in which larger nanoparticles have a much greater effect) and the 
PDI (0.332). 3.6 was larger, 193 nm in diameter by DLS (Table 3-1, Figure 3-7) but has a 
monodisperse size distribution with a polydispersity index (PDI) of 0.122. These results 
suggest that 3.6 forms discrete nanoparticles in solution, which exhibit some hydrogel-like 
behavior with the negatively-charged silanol and carboxylic acid groups within 3.6 repelling 
each other in aqueous solution. The higher equivalents of TEOS in 3.6 would make the 
nanoparticles behave more like silica nanoparticles, which tend to form discrete nanoparticles 
under these synthesis conditions.  The zeta potentials of 3.5 and 3.6 were -25.1 and -29.75 
due to the negatively charged silanol and carboxylic acids present on the nanoparticle 
surface. TGA analysis of 3.5 closely matched the feed conditions, with 4.7 SiO2 molecules 
per platinum (Figure 3-8) and ICP-MS further confirmed the cisplatin loading of 25.4- 30.8% 
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cisplatin by weight (hypothetical 29.9%).  3.6 had a slight overincorporation of TEOS 
compared to the hypothetical with 12.5 SiO2 units per platinum center (Figure 3-8). The 
cisplatin loading of 3.6 was 14-20 wt% (hypothetical 20.3%). These platinum loadings 
translate into approximately 62,500 (3.5) or 106,000 (3.6) cisplatins per nanoparticle, which 
is much higher than other nanoparticle systems for cisplatin delivery36-40 and rivals other high 
platinum loading platforms. 14, 41-43  
 
Figure 3-4: SEM micrographs of 3.5 (A) and 3.6 (B). 
 
Figure 3-5: TEM micrographs of 3.5 (A) and 3.6 (B). 
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Figure 3-6: High resolution TEM images of 3.6. Scale bar is 5 nm for the left image and 10 
nm for the right image. 
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Figure 3-7: Intensity (left) and number (right) weighted DLS spectra of 3.5 (blue) and 3.6 
(red) obtained in 5mM PBS. 
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Figure 3-8: TGA weight loss curves for 3.5 (blue) and 3.6 (red) 
 
3.2.3 cRGD Targeting of Nanoparticle 3.6 
 A variety of different strategies have been developed to post-synthetically modify 
silica nanoparticles.16, 21, 25, 44 For covalent post-synthetic modification, silica nanoparticles 
can be modified through surface silanol groups with a variety of silyl-derived molecules. 
Alternatively, an orthogonal functional group can be placed onto the nanoparticle surface to 
allow for further modification.  For the nanoparticles discussed in this chapter, the latter 
strategy is adapted since DSCP-Si, when condensed into the silica matrix, presents 
carboxylic acids on the nanoparticle surface.  
 Nanoparticle 3.6 was modified with a cancer targeted peptide, cRGDfK, by an amide 
coupling reaction between the surface carboxylic acids and the primary amine group on the 
peptide for conjugation (Scheme 3-3). The carboxylic acid groups are activated via the 
formation of an activated NHS ester intermediate, which then reacts with the amine group on 
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the peptide to form the amide bond. cRGD targets the αvβ3 integrin, which is overexpressed 
on a wide variety of different cancers. 45-47 There was no change in particle morphology by 
SEM (Figure 3-9) as a result of peptide modification. However, the nanoparticles were 
slightly larger by DLS, (Table 3-1, Figure 3-10) with a hydrodynamic diameter of 222 nm.  
The increase in hydrodynamic diameter is within the error range of the DLS (as a function of 
PDI), so cRGD conjugation has little, if any, effect on nanoparticle size. Peptide conjugation 
increased the zeta potential to -21.1 mV (Table 3-1) as a result of charge attenuation with the 
neutral cRGD peptide. The drug loading, measured by ICP-MS, also did not substantially 
change as a result of peptide conjugation. 
 
Scheme 3-3: Post-synthetic modification scheme of 3.6. 3.6 is first activated to form an 
active NHS ester, which then reacts with amine groups on cRGDfK to create RGD-3.6 
 
Figure 3-9: SEM image of RGD-3.6 
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Figure 3-10: Intensity (left) and number (right) weighted DLS spectra of 3.6 (red) and RGD-
3.6 (black) obtained in 5mM PBS.  
 
3.2.4 Platinum Release from Nanoparticle 3.6 
 We would expect the synthesized nanoparticles to be stable under normal 
physiological conditions due to the robust nature of the silica matrix. However, once the 
nanoparticles are internalized by cells or reach the tumor microenvironment, the platinum 
(IV) centers would be rapidly reduced by endogenous biomolecules, releasing cisplatin to 
exert its anticancer activity.  As a proof of concept, we tested platinum release from 3.6 
(Figure 3-11). In the absence in any reducing agent (t<0), there is no background platinum 
release from 3.6 due to the strong silsesquioxane linkages anchoring the platinum centers to 
the nanoparticle matrix.  With the addition of 5mM glutathione, which would roughly 
correspond to intracellular concentrations of thiol-containing reducing agents, a rapid release 
of 44% of the total platinum payload was observed after 2 hours of incubation, followed by a 
more gradual release of remaining platinum over the next 4 days. This biphasic release has 
been previously observed in the development of oxaliplatin-based PSQ nanoparticles (as 
discussed in the previous chapter).42 We believe that the first, initial burst release is 
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composed mostly of platinum centers found at or near the nanoparticle surface. The second, 
more sustained drug release comes from platinum centers located in the core, as glutathione 
would need to diffuse further into the silica matrix to reduce and release the platinum centers.   
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Figure 3.11: Platinum release from 3.6 can be triggered by the addition of an endogenous 
reducing agent (indicated by arrow) in this case 5mM glutathione. 
3.2.5 In Vitro Cytotoxicity Assays 
 3.6 was evaluated in vitro against two human non-small cell lung cancer cell lines: 
A549 and NCI-H460.  We chose to evaluate these nanoparticles against non-small cell lung 
cancer because that cisplatin is a widely used chemotherapeutic for lung cancer treatment and 
that lung cancer is the most common form of cancer in the US.2 In the A549 cell line, 3.6 
showed no activity across the concentration range evaluated (Figure 3-12). These results are 
not entirely unexpected, as 3.6 has a negative charge and would be unable to cross the cell 
membrane easily. If the nanoparticles are not internalized, then we would not expect to see 
any drug release due to the stability of 3.6 and the low concentrations of reducing agents in 
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cell media.  Additionally, cell media does not possess a high concentration of reducing agents 
(typically sub-millimolar) to induce an appreciable amount of platinum release from 3.6 over 
the time-frame of the assay. Cisplatin was highly effective with an IC50 of 0.77 µM.  A549 
cells overexpress the αvβ3 integrin,48-49 so RGD-3.6 would be expected to provide an increase 
in efficacy over 3.6. Indeed, RGD-3.6 had an IC50 value of 1.18 µM, which is comparable to 
cisplatin, presumably due to the increase in nanoparticle uptake by receptor-mediated 
endocytosis. In the H460 cell line, 3.6 had modest efficacy with an IC50 of 13.85 µM, but 
was not nearly as effective as cisplatin, which possessed an IC50 of 1.86 µM (Figure 3.-3).  
The difference in efficacy is presumably due to the ineffective endocytosis of 3.6. H460 cells 
also express the αvβ3 integrin,50 so RGD-3.6 (IC50= 4.46 µM) was more effective than 3.6, 
but it was not more effective than cisplatin. RGD targeting appears to have increased the 
extent of endocytosis, but not enough for equal efficacy as cisplatin.  
0 10 20 30
0
50
100
 
 
P
er
ce
nt
 C
el
l V
ia
bi
lit
y
Platinum Concentration (μM)
 Cisplatin
 3.6
 RGD-3.6
 
Figure 3-12: Cell viability assay of cisplatin (black), 3.6 (red), and RGD-3.6 (blue) 
evaluated against A549 human lung carcinoma cells.  
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Figure 3-13: Cell viability assay of cisplatin (black), 3.6 (red), and RGD-3.6 (blue) 
evaluated against NCI-H460 human lung carcinoma cells.  
 
3.3 Conclusion 
 In this chapter, a series of silica nanoparticles with co-condensed cisplatin prodrugs 
were synthesized. The nanoparticle size and drug loading could be controlled by varying the 
platinum to TEOS molar ratio in the synthesis or by changing the reaction time. Platinum 
release from these nanoparticles could be triggered by exposure to intracellular 
concentrations of biologically-relevant reducing agents such as glutathione.  Nanoparticles 
with 10 molar equivalents of TEOS were targeted to cancer cells by conjugating a cyclic-
RGD peptide onto the nanoparticle surface.  These nanoparticles were evaluated in vitro 
against two human non-small cell lung cancer cell lines. The unfunctionalized nanoparticles 
possessed little activity against these cell lines as their negative charge would hinder 
endocytosis and cell media does not have enough reducing agents present to induce a 
significant extent of drug release. RGD targeting these nanoparticles could increase their 
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efficacy to that of cisplatin. Due to the development of a more promising cisplatin-PSQ 
nanoparticle (discussed in the next chapter) and the lack of an efficiently pegylated 
nanoparticle, the development of these co-condensed silica nanoparticles was halted after the 
initial in vitro studies. Further work would be needed to create an effectively pegylated 
species for in vivo evaluation. 
3.4 Materials and Methods 
3.4.1 General Materials and Methods 
All chemicals were purchased from Fisher or Aldrich and used without purification 
unless noted. Cisplatin was purchased from AK Scientific. Tetrahydrofuran was dried by the 
sodium metal/benzophenone method. Dimethylformamide was dried by passing through an 
activated alumina column. Thermogravimetric analysis was performed using a Shimadzu 
TGA-50 equipped with a platinum pan and heated at 3°C per minute in air. A Hitachi 4700 
field emission scanning electron microscope and a JEM 100CX-2 transmission electron 
microscope (TEM) were used to determine particle size and morphology. SEM and TEM 
samples were prepared from ethanolic suspensions of the nanoparticles dropped onto glass 
slides or amorphous carbon-coated copper grids. The solvent was then allowed to evaporate.  
A Cressington 108 Auto Sputter Coater equipped with an Au/Pd (80/20) target and a MTM-
10 thickness monitor was used to coat SEM samples with a 4 nm thick conductive layer prior 
to obtaining SEM images. Dynamic light scattering (DLS) and zeta potential measurements 
were made using a Malvern Instruments Zetasizer Nano.  Inductively-Coupled Plasma Mass 
Spectrometry (ICP-MS) measurements were made using a Varian 820-MS Inductively-
Coupled Plasma Mass Spectrometer. ICP-MS samples were prepared by digesting a known 
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amount of sample in concentrated nitric acid overnight and then diluting with water to 2% 
nitric acid by volume.  
3.4.2 Synthesis of Platinum Complexes 
Synthesis of c,c,t-Pt(NH3)2Cl2(OH)2 
The platinum complex c,c,t-Pt(NH3)2Cl2(OH)2 was synthesized by a previously reported 
method with minor changes.14   A suspension of cisplatin (cis-Pt(NH3)2Cl2) (2.50 g, 8.3 
mmol) and 30 wt% hydrogen peroxide (H2O2) (14 mL, 125 mmol) in water (113 mL) was 
heated to 70°C for 5 hours in the dark. The heat was removed and stirring was continued 
overnight at room temperature. The resulting yellow suspension was concentrated under 
rotary evaporation to 10 mL and the product was allowed to precipitate at 4°C for several 
hours. The product was collected via filtration, washed with water, ethanol, and diethyl ether, 
and vacuum dried.  The product was obtained as a bright yellow powder. Yield: 2.07 g (75% 
yield). 
Synthesis of c,c,t-Pt(NH3)2Cl2(triethoxysilylpropyl succinic acid)2 (DSCPSi) 
Two hundred milligrams of c,c,t-Pt(NH3)2Cl2(OH)2 (0.6 mmol) was suspended in 4 mL of 
anhydrous DMF.  To this, 700 μL of triethoxysilylpropyl succinic anhydride was added (1.8 
mmol). The resulting suspension was stirred under argon at 50°C for 3 days, yielding a clear 
yellow solution. Two volume equivalents of triethylamine was added to precipitate the 
product.  The product was isolated by centrifugation and washed twice with diethyl ether 
before drying under high vacuum, yielding a yellow brown crystalline material. The product 
was stored at -20°C. Yield 440 mg (78%). 1H NMR (DMSO-d6): 6.25(6H, NH3), 3.73 (12H, 
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OCH2), 2.75 (4H, CH2), 2.31 (2H, CH), 1.45 (4H, CH2); 1.32 (4H, CH2), 1.12 (18H, CH3); 
0.52 (4H, CH2) 
3.4. 3 Nanoparticle Synthesis 
All nanoparticles were synthesized within a reverse microemulsion. An organic stock 
solution of 0.3 M Triton X-100 and 1.5 M 1-hexanol in cyclohexanes was created by mixing 
Triton X100 (93.75g, 0.15mol) and 1-hexanol (76.5 g, 0.75 mol) into a 500 mL volumetric 
flask. The flask was filled to the mark with cyclohexanes.  
Synthesis of 3-1, 3-2, 3-3, and 3-4 
A solution of 0.3 M Triton X100 and 1.5 M 1-hexanol in cyclohexanes (35 mL) was placed 
into a 100 mL round bottom flask. DSCP-Si (22mg, 23µmol) was dissolved into 770 µL of 
water.  The aqueous portion was added to the organic and X equivalents (X=5, 10,15,20) of 
TEOS were added. The resulting microemulsion was stirred for 10 minutes until optically 
transparent and 600 µL of aqueous ammonia was added (w=7.5). The microemulsion was 
stirred at room temperature in the dark for 3 hours and then an equal volume of ethanol was 
added to quench the reaction. The particles were isolated by centrifugation (13,000 rpm for 
15 minutes) and washed with ethanol three times. The resulting nanoparticles were 
characterized by SEM, DLS and TGA.  
Synthesis of 3-5 and 3-6 
3-5 and 3-6 were synthesized by a slight modification of the procedure above. A solution of 
0.3 M Triton X-100, 1.5 M 1-hexanol in cyclohexanes (35mL) was placed in a round bottom 
flask. DSCP-Si (22mg, 23 µmol) was dissolved into 770 µL of water. The aqueous solution 
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was added to the organic and either 5 or 10 equivalents of TEOS was then added. The 
microemulsion was stirred for 10 minutes and 600 µL of aqueous ammonium hydroxide was 
added. The microemulsion was then stirred for 24 hours at room temperature in the dark. An 
equal volume of ethanol was added to quench the reaction and the particles were isolated by 
centrifugation (13,000 rpm x 15 minutes) and washed with ethanol three times. The 
nanoparticles were stored in ethanol. 
3.4.4 Nanoparticle Surface Modification 
Synthesis of cRGDfK targeted 3.6 
As-synthesized nanoparticles (10 mg) were resuspended into 4 mL of a freshly made 0.025 
M NHS/EDC solution in water. The nanoparticle suspension was heated at 50°C for 2 hours 
to activate the acid as an NHS ester before the suspension was cooled to room temperature. 
cRGDfK (Peptides International, 0.6 mg, 0.96 µmol) was added and the suspension was 
stirred overnight. Nanoparticles were isolated by centrifugation and washed with water once 
and ethanol once. The particles were stored in ethanol.  
3.4.5 Platinum Release from 3.6 
Two milligrams of 3-6 was isolated by centrifugation and redispersed into 1mL 2mM 
HEPES buffer. The suspension was loaded into a 3500 MW weight cutoff dialysis bag and 
the bag was added to 479 mL of the same buffer. The solution was sparged with argon for 10 
minutes and heated to 37°C. The solution was incubated under an Ar blanket for 24 hours, 
with aliquots of the dialysate periodically removed. After 24 hours, an oxygen free solution 
of glutathione was added to make a total glutathione concentraton of 5 mM. The solution was 
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incubated at 37°C with aliquots periodically removed. Platinum concentration within the 
dialysis aliquots was determined by ICP-MS. 
3.4.6 In Vitro Assays 
General: NCI-H460 human large cell lung carcinoma (ATCC# HTB-177), A549 human lung 
carcinoma cells (ATCC# CCL-185), and PC-3 human prostate adenocarcinoma cells 
(ATCC# CRL-1435) were all purchased from the Tissue Culture Facility of the Lineberger 
Comprehensive Cancer Center. All cell culture reagents were purchased from the Tissue 
Culture Facility in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.  All 
cells were maintained at 37°C with 5% CO2 and were cultured according to ATCC 
recommendations. 
Cell Viability Assay: A549 Cells 
Confluent A549 cells were plated in 6 well plates at a density of 100,000 cells/well (3mL 
media). The plates were incubated overnight to promote cell attachment. After incubation, 
the plates were removed from the incubator and the media was removed once. Each well was 
washed once with PBS and refilled with 3 mL media with various concentrations of 
platinum.  The plates were incubated for 72 hours and cell viability was determined by trypan 
blue dye exclusion. 
Cell Viability Assay: H460 cells 
Confluent H460 cells were plated in 6 well plates at a density of 50,000 cells/well (3mL 
media). The plates were incubated overnight to promote cell attachment. After incubation, 
the plates were removed from the incubator and the media was removed. Each well was 
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washed once with PBS and refilled with 3mL media with various concentrations of platinum.  
The plates were incubated for 72 hours, with the media removed and replaced on the second 
day. Cell viability was determined by trypan blue dye exclusion. 
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Chapter 4: 
Cisplatin-containing Polysilsesquioxane Nanoparticles for Chemotherapy and 
Chemoradiotherapy of Lung Cancer 
4.1 Introduction 
 Our laboratory has recently developed a new nanoparticle platform, known as 
polysilsesquioxane (PSQ), for anticancer drug delivery.1  PSQ is a type of hybrid material 
composed of siloxane networks with organic or metal organic bridging ligands. These 
materials are synthesized from bis(trialkoxysilanes) ((R'O)3Si-R-Si(OR')3) by sol-gel 
synthesis.2-3 Our laboratory incorporated a derivative of the anticancer drug oxaliplatin into 
PSQ nanoparticles at very high loadings (up to 47 wt%). Preliminary in vivo evaluations 
demonstrated that oxaliplatin-PSQ nanoparticles possessed improved efficacy over 
oxaliplatin in a pancreatic cancer xenograft model.  
We wished to extend the PSQ platform to deliver the platinum anticancer drug 
cisplatin, as cisplatin receives more general use than oxaliplatin. Cisplatin is used for the 
treatment of a variety of cancers, including testicular, lung, breast, and ovarian cancers.4-5 In 
addition, it is used for the chemoradiotherapy treatment of head and neck, esophageal, lung, 
cervical, and anal cancers.6-9  However, cisplatin treatment has limitations, most notably its 
high general toxicity and resistance against some cancers.10-11 This chapter reports the 
extension of the PSQ nanocarrier for the delivery of cisplatin to cancer cells. We have carried 
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out the detailed physiochemical characterization and demonstrated triggered drug release, in 
vitro cytotoxicity, and in vivo efficacy of cisplatin-containing PSQ nanoparticles.  
4.2 Results and Discussion 
4.2.1 Platinum Complex Synthesis 
 The platinum complex DSCP-Si (DSCP-Si= c,c,t-Pt(NH3)2Cl2(triethoxysilylpropyl 
succinate)2) was synthesized as described in the previous chapter, starting from commercially 
available cisplatin (Scheme 3-1).  DSCP-Si has two triethoxysilyl groups to allow for 
polymerization into PSQ nanoparticles and two carboxylic acid groups to allow for further 
nanoparticle surface modification. 
4.2.2 Synthesis of Nanoparticle 4.1 
PSQ particle 4.1 was synthesized via a base catalyzed sol-gel polymerization in a 
mixture of ethanol, water, and ammonia and then purified by ion-exchange chromatography, 
dialysis, and centrifugation (Scheme 4-1). The nanoparticle synthesis is similar to the 
classical Stöber synthesis of silica nanoparticles.12-13 The isolated nanoparticles were 
characterized by transmission electron microscopy (TEM), scanning electron microscopy 
(SEM), dynamic light scattering (DLS), thermogravimetric analysis (TGA), and inductively 
coupled - plasma mass spectrometry (ICP-MS). 4.1 is 64 nm in diameter by TEM (Figure 4-
1), with SEM showing a similar diameter (Figure 4-2). Under physiological conditions, 4.1 
shows hydrogel-like behavior and swells to a diameter of 134.2 nm (Figure 4-3, Table 4-1) 
by DLS.  4.1 possesses a highly negative zeta potential (Table 4-1) due to deprotonation of 
surface silanol and carboxylic acid groups.  TGA of 4.1 (Figure 4-4) gave the expected 
weight loss for the completely condensed nanoparticle, indicating that 4.1 was a 
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homopolymer of completely polymerized DSCP-Si. TGA measurements suggested a 
cisplatin loading of 42 wt%, which was confirmed by ICP-MS measurements of the platinum 
content. This impressive cisplatin loading corresponds to approximately 1.15x105 cisplatin 
molecules/ nanoparticle. The cisplatin loading is higher, by up to 4 orders of magnitude, than 
other cisplatin nanoparticle drug delivery platforms. 14-21 For example, Lippard and 
coworkers reported two carbon nanotube-based systems, containing between 65-82 Pt 
centers, to deliver Pt(IV) prodrugs similar to DSCP-Si.16, 20 The cisplatin loading of 4.1 is 
slightly less than that of the PSQ nanoparticles for oxaliplatin delivery on a per weight basis 
because of the higher molecular weight of the oxaliplatin prodrug, but has a similar agent 
loading on a per number basis.1 
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Scheme 4-1: Schematic of the synthesis of 4.1. Drug release can be triggered by endogenous 
reducing agents with the released drug leading to various anticancer effects. 
 
Figure 4-1: TEM micrographs of 4.1. 
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Figure 4-2: SEM micrographs of 4.1. 
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Figure 4-3: Intensity (left) and number (right) weighted DLS spectra for 4.1 obtained in 5 
mM PBS. 
 
Table 4-1: Hydrodynamic diameters and zeta potentials of various forms of 4.1. All DLS 
measurements were obtained in 5 mM PBS and are the average of 3 measurements. 
Particle ID Z Average (nm) PDI Intensity 
Average (nm) 
Number 
Average (nm) 
Zeta Potential 
(mV) 
4.1 135.2 ± 0.5 0.07 ± .01 147.9 ± 0.8 101.5 ± 1.2 -41.9 + 2.4 
RGD-4.1 129.1± 0.4 0.10 ± 0.01 142.7 ± 1.5 95.2 ± 1.8 -17.7 ± 0.6 
PEG2k-4.1 195.9 ± 2 0.13 ± 0.02 217.7 + 2.3 147.9 ± 3.1 -2.9 ± 1.5  
APEG2k-4.1 201.3 ± 1.1 .09 + ± 0.01 221.2 + 1.6 165.4 ± 2.2 -3.9 +2.3 
PEG5k-4.1 150.3 ± 5  0.09 ± 0.01 165.9 ± 5.8 114.0 ± 5.3 -6.5 ± 0.4 
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Figure 4-4: TGA weight loss curve for 4.1. 
4.2.3 Cisplatin Release from Nanoparticle 4.1 
Nanoparticle 4.1 was designed to show minimal drug release under normal 
physiological conditions, but to rapidly release cisplatin within the tumor microenvironment 
or upon cellular internalization (Scheme 4-1). Platinum release from 4.1 was measured by 
ICP-MS (Figure 4-5) in the presence of L-cysteine, a surrogate cellular reducing agent. In the 
absence of any reducing agent, 4.1 shows a burst release of 9-15% of the total payload, but 
no additional release is observed after the initial release. This is most likely due to some 
weakly physisorbed DSCP-Si on the nanoparticle surface. In the presence of 15 µM of L-
cysteine (Figure 4-5, red line), there is a very slow, sustained release of platinum from 4.1, 
with only 30% of the total amount of platinum released after 73 hours of incubation. 
However, in the presence of 5 mM L-cysteine (Figure 4-5, blue line), 45% of the total 
platinum is released within 5 hours, with the remaining platinum released gradually over the 
next 50 hours.  The biphasic release is due to the covalent nature of the PSQ matrix. We 
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believe that the initial burst release of platinum arises from platinum centers at or near the 
nanoparticle surface. The longer sustained platinum release arises from platinum centers in 
the core of the nanoparticle, as L-cysteine would need to diffuse progressively further into 
the nanoparticle interior to reduce and release the platinum. These results suggest that 4.1 
would show minimal drug release in circulation, but when placed in a highly reducing 
environment, such as the tumor microenvironment or upon cellular internalization, cisplatin 
would be rapidly released from the PSQ matrix, leading to more pronounced antitumor 
effects.  
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Figure 4-5: Platinum Release from 4.1 in the presence of low (15 µM, red line) or high (5 
mM, blue line) concentrations of L-cysteine as a model reducing agent. L-cysteine was added 
at time zero, as indicated by the black arrow.  
 
4.2.4 cRGD targeting 
The presence of carboxylic acids on the surface of 4.1 allows the nanoparticles to be 
post-synthetically modified to further improve its surface properties. First, the cRGD peptide 
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was conjugated to 4.1 via an amide linkage to afford RGD-4.1 (Scheme 4-2). The cRGD 
peptide primarily targets the αvβ3 integrin, which is upregulated on a variety of different 
tumor types.22-23 cRGD conjugation to 4.1 (RGD-4.1) was accomplished by pre-activating 
the carboxylic acids on 4.1 with EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) and 
NHS (N-hydroxysuccinimide) to form a more reactive NHS ester, which would then form an 
amide bond with the lysine residue on cRGDfK. The lysine residue was engineered onto the 
peptide for conjugation, so the activity of the peptide would not be compromised. RGD-4.1 
showed no difference in particle morphology by SEM (Figure 4.6). By DLS, RGD-4.1 was 
actually slightly smaller than 4.1 (Figure 4.7, Table 4.1), but the differences in the two values 
are within experimental error. The zeta potential of RGD-4.1 shifted to a more neutral value 
of -17.7 mV, indicating coating by the neutral cRGD peptide (Table 4.1). The drug loading, 
measured by ICP-MS, was unaffected by peptide conjugation. 
 
Scheme 4-2: Post-synthetic modification of 4.1 to form RGD-4.1 
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Figure 4-6: SEM micrographs of RGD-4.1. 
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Figure 4-7: Intensity (left) and number (right) weighted DLS spectra of 4.1 (black) and 
RGD-4.1 (red) obtained in 5 mM PBS. 
 
4.2.5 In Vitro Cytotoxicity of 4.1 and RGD-4.1 
4.1 and RGD-4.1 were evaluated in vitro against 3 cancer cell lines: A549 lung 
adenocarcinoma, NCI-H460 large cell lung carcinoma, and PC-3 prostate adenocarcinoma. 
We chose to evaluate these nanoparticles against models of lung and prostate cancer as 
cisplatin is part of the standard of care for these two cancers.24-25 In the A549 cell line, 4.1 
was nearly twice as effective as cisplatin (Figure 4-8, Table 4-2). The αvβ3 integrin is 
overexpressed in A549 cells,26 so RGD-4.1 had an IC50 value one-half that of 4.1 and nearly 
one-quarter of cisplatin (Table 4-2). Cisplatin was more cytotoxic than 4.1 in H460 cells; 
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however, RGD-4.1 possessed nearly 4 fold-better efficacy than 4.1, and slightly better 
cytotoxicity than cisplatin itself (Figure 4-9, Table 4-2) as H460 cells overexpress the αvβ3 
integrin.27 PC-3 cells do not overexpress the αvβ3 integrin, so RGD targeting would not be 
effective.28 Indeed, RGD-4.1 had nearly identical efficacy as 4.1, both of which were 2.5 
times more effective than cisplatin (Figure 4-10, Table 4-2).   
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Figure 4-8: Cell viability assay of A549 lung adenocarcinoma cells treated with cisplatin 
(black), 4.1 (red) or RGD-4.1 (blue). 
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Figure 4-9: Cell viability assay of H460 large cell lung carcinoma cells treated with cisplatin 
(black), 4.1 (red) or RGD-4.1 (blue). 
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Figure 4-10: Cell viability assay of PC-3 prostate adenocarcinoma cells treated with cisplatin 
(black), 4.1 (red) or RGD-4.1 (blue). 
Table 4-2: IC50 values of cisplatin, 4.1, and RGD-4.1 evaluated against three cancer cell 
lines. 
Cell Line Cisplatin IC50 (µM) Cisplatin-PSQ IC50 (µM) RGD-Cisplatin-PSQ IC50 (µM)
A549  0.95 0.55 0.25 
NCI-H460 0.96 2.65 0.702 
PC-3 1.66 0.675 0.659 
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4.2.6 Pegylation of 4.1 
 Encouraged by the initial results, which demonstrated that 4.1 possessed triggered 
drug release and in vitro efficacy against a panel of cancer cell lines, we decided to evaluate 
4.1 in vivo against murine cancer models. First, polyethylene glycol (PEG) was also 
conjugated to the surface of 4.1. PEG is an inert, biocompatible polymer which is widely 
used to improve the biocompatibility, to reduce mononuclear phagocytic system (MPS) 
uptake, and to improve efficacy of nanomaterials.29-32 Amine-terminated polyethylene glycol 
monomethyl ether (MW=2000) first was synthesized by an established procedure with minor 
modifications.33 This PEG could be conjugated to 4.1 by an EDC-mediated amide coupling 
to form PEG2k-4.1. As-synthesized PEG2k-4.1 demonstrated no change in particle 
morphology by SEM (Figure 4-11). Under physiological conditions, PEG2k-4.1 has a larger 
hydrodynamic diameter [d(Zavg) = 195.9 nm] than 4.1 ([d(Zavg) = 134.2 nm] (Figure 4-12, 
Table 4-1).  An increase in hydrodynamic diameter would be expected due to the PEG chains 
extending away from the nanoparticle surface, but it would not be expected to alter the size 
to this extent. There also may be a very slight increase in aggregation as a result of PEG 
conjugation. The zeta potential after PEG conjugation increased to -2.9 mV, which would be 
indicative of a PEG surface layer shielding the negative charge of the nanomaterial (Table 4-
1).30 TGA measurements of PEG2k-4.1 showed an increase in weight loss of 20%, 
attributable to the PEG layer on the nanoparticle surface (Figure 4-13). This weight loss 
would correspond to a dense PEG surface coverage of 1.02 PEG/ nm2. At this coverage 
density, PEG would be expected to adopt the desired brush confirmation to resist plasma 
protein binding and would allow the particle to evade the MPS system for efficient in vivo 
applications.32  
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Figure 4-11: SEM micrographs of PEG2k-4.1 (left) and APEG2k-4.1 (right).  
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Figure 4-12: Intensity (left) and number (right) weighted DLS spectra of 4.1 (black), 
PEG2k-4.1 (red) and APEG2k-4.1 (blue) obtained in 5mM PBS. 
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Figure 4-13: TGA weight loss curves for 4.1 (black), PEG2k-4.1(red), and APEG2k-4.1 
(blue). 
An anisamide targeted, pegylated version of 4.1 (APEG2k-4.1) was synthesized as 
well. The anisamide ligand targets the sigma receptor, an opioid receptor overexpressed on a 
variety of cancer cells.34-38 PEG with one anisamide and one amine end group was 
synthesized by an amide coupling between p-methoxybenzoic acid and 
diamminopolyethylene glycol (MW= 2000). The desired PEG was isolated from the reaction 
byproducts by column chromatography.  To synthesize APEG2k-4.1, the same procedure for 
the preparation of PEG2k-4.1 was followed except that 10 mol% anisamide PEG was added. 
Only 10 mol % of the APEG2k agent was used as prior studies suggest that about 10 mol % 
targeting ligand is necessary to achieve targeting in vivo and higher fractions may reduce the 
shielding effects of PEG.39-40 APEG2k-4.1 was characterized by SEM, DLS, zeta potential, 
TGA and ICP-MS (Figures 4-11 - 4-13, Table 4-1) and had no appreciable differences from 
PEG2k-4.1. 
 
133 
 
 
4.2.7 In vitro cytotoxicity of PEG2k-4.1 and APEG2k-4.1 
 PEG2k-4.1 and APEG2k-4.1 were evaluated in vitro against two non-small cell lung 
cancer lines: A549 and H460. In the A549 cell line, PEG2k-4.1 was highly effective, but it 
was not quite as effective as cisplatin under the same conditions (Figure 4-14, Table 4-3). 
Previous assays had demonstrated that the unmodified 4.1 was much more effective than 
cisplatin (Figure 4-8, Table 4-2), so the PEG layer, which is designed to prevent nanoparticle 
uptake by MPS organs, lessened the degree of endocytosis and reduced efficacy in A549 
cells. PEG2k-4.1, APEG2k-4.1 and 4.1 were evaluated in H460 cells (Figure 4-15, Table 4-
3). H460 cells overexpress the sigma receptor, so using an anisamide targeted nanoparticle 
would be appropriate.41-42 All three forms of 4.1 showed better efficacy than cisplatin with 
4.1 and PEG2k-4.1 having comparable IC50 values. Anisamide targeting increased the 
efficacy approximately 3 times compared to the other nanoparticles and 6 times over 
cisplatin. Based on these promising in vitro results, PEG2k-4.1 and PEG5k-4.1 were chosen 
for further in vivo evaluations.  
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Figure 4-14: Cell viability assay of A549 lung adenocarcinoma cells treated with either 
cisplatin (black) or PEG2k-4.1 (red). 
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Figure 4-15: Cell Viability assay of H460 large cell lung carcinoma cells treated with either 
cisplatin (black), 4.1 (green), PEG2k-4.1 (red) or APEG2k-4.1 (blue).  
 
 
 
135 
 
Table 4-3: IC50 values of cisplatin, 4.1, PEG2k-4.1, and APEG2k-4.1 evaluated against two 
NSCLC cell lines. 
Cell Line Cisplatin (µM) 4.1 (µM) PEG2k-4.1 (µM) APEG2k-4.1 (µM) 
A549 0.676 N.A. 1.27 N.A. 
H460 2.04 0.92 1.03 0.33 
 
4.2.8: In Vivo Efficacy of PEG2k-4.1 and APEG2k-4.1 
 Based on the encouraging in vitro results which demonstrated that both PEG2k-4.1 
and APEG2k-4.1 were efficacious in multiple cancer cell lines, we evaluated 
chemotherapeutic efficacy of the PSQ particles in vivo against a H460 lung cancer xenograft 
model (Figure 4-16). Nu/Nu mice were implanted with H460 cells subcutaneously and the 
tumors were allowed to grow until palpable. The mice were randomly split into 4 groups (7-8 
mice per group) and received either saline control, cisplatin (4 mg/kg), PEG2k-4.1 (4 mg 
cisplatin/kg equivalent), APEG2k-4.1 (4 mg cisplatin/kg equivalent) on days 0, 2 and 4. 
Tumor growth was measured by caliper measurements and the study was terminated when 
the control mice reached the maximum allowed size by the IACUC guidelines. Mice 
receiving no treatment showed rapid tumor growth, reaching the allowed size limits 15 days 
after commencement of the study. Mice receiving all of the platinum treatments 
demonstrated statistically significant tumor growth inhibition over the control mice, but all 
platinum treatment provided nearly identical tumor growth inhibition. Unfortunately, the 
treatments with all of the platinum formulations were too aggressive and treatment related 
deaths were observed in all treatment groups (Table 4-4). Surviving mice weights remained 
relatively constant, with some weight gain throughout the study (Figure 4-17). After the 
conclusion of the study, the tumors were resected and analyzed by histology (Figures 4-18 -
4-20). Mice receiving no treatment showed large tumors with viable and necrotic regions. 
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The necrotic regions are due to a lack of nutrients in the core of the tumor. Cisplatin 
treatment increased the area of the necrotic tumor regions compared to the control mice, but 
did not eradicate all of the cells in the tumor region. On the other hand, mice receiving 
PEG2k-4.1 or APEG2k-4.1treatment had tumors composed of large necrotic centers, with 
viable cells found only on the periphery of the tumor. The histology results suggest that the 
PSQ particles are highly effective chemotherapeutics, but that the treatments were too harsh 
and resulted in death caused by the toxicity of the platinum formulations.  
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Figure 4-16: Tumor growth inhibition in a H460 large cell lung carcinoma subcutaneous 
xenograft model. Mice received either saline control (black), cisplatin (green, 4 mg/kg), 
PEG2k-4.1 (red, 4 mg cisplatin/kg equivalent), or APEG2k-4.1 (blue, 4mg cisplatin/kg 
equivalent) on days 0, 2, and 4.  
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Figure 4-17: Mouse body weight changes during the course of the study. Mice received 
either saline control (black), cisplatin (green, 4 mg/kg), PEG2k-4.1 (red, 4 mg cisplatin/kg 
equivalent), or APEG2k-4.1 (blue, 4 mg cisplatin/kg equivalent) on days 0, 2, and 4.  
Table 4-4: Mouse survival statistics as a result of platinum chemotherapy  
Treatment Group Treatment Related Deaths Death Percentage 
Control 0/7 0% 
Cisplatin 3/7 43% 
PEG2k-4.1 3/7 43% 
APEG2k-4.1 3/7 43% 
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Figure 4-18: Histological images of resected H460 tumors with H&E staining at 4x 
magnification. Mice received either saline control (A), cisplatin (B), PEG2k-4.1 (C), or 
APEG2k-4.1(D) on study days 0, 2, and 4. The blue-purple dots result from nuclear staining 
of viable cancer cells whereas the pinkish areas are necrotic regions containing no viable 
tumor tissue. Scale bar indicates 0.5 mm.  
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Figure 4-19: Histological images of resected H460 tumors with H&E staining at 10x 
magnification. Mice received either saline control (A), cisplatin (B), PEG2k-4.1 (C), or 
APEG2k-4.1(D) on study days 0, 2, and 4. The blue-purple dots result from nuclear staining 
of viable cancer cells whereas the pinkish areas are necrotic regions containing no viable 
tumor tissue. Scale bars indicate 0.5 mm. 
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Figure 4-20: Histological images of resected H460 tumors with H&E staining at 20x 
magnification. Mice received either saline control (A), cisplatin (B), PEG2k-4.1 (C), or 
APEG2k-4.1(D) on study days 0, 2, and 4. The blue-purple dots result from nuclear staining 
of viable cancer cells whereas the pinkish areas are necrotic regions containing no viable 
tumor tissue. Scale bars indicate 120 µm. 
4.2.9 Maximum Tolerated Dose Studies of PEG2k-4.1 
 In order to avoid the toxicity-related mouse death observed in the previous xenograft 
study, maximum tolerated dose (MTD) studies were performed on PEG2k-4.1. MTD is 
defined as the highest dose level that does not cause death, a body condition score less than 
or equal to two,43 or greater than 20% body weight loss. Violation of the latter two 
parameters would result in the immediate euthanasia of the mouse due to the IACUC 
guidelines. Non-tumor bearing mice were administered a single i.v. dose of PEG-4.1 and 
mice were monitored daily. Survival, with no adverse effects, for two weeks post-injection 
was considered a safe dose level. The MTD of cisplatin, under this injection schedule was 10 
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mg/kg.44-45 PEG2k-4.1 possessed a much lower MTD than cisplatin, with animal death 
observed at a 4 mg/kg cisplatin dose (Table 4-5). These results suggest that PEG2k-4.1 has 
high, off target organ toxicity, which would limit its clinical application.  ICP-MS analysis of 
the resected MPS system organs demonstrated that the liver had the highest platinum 
accumulation post-injection, which was further verified by liver histology (Figure 4-21). The 
liver from the mouse receiving PEG2k-4.1 had large necrotic regions, with a significant 
amount of red blood cells leaving circulation and pooling in the liver. Due to this toxicity, 4.1 
was reformulated to attempt to improve its in vivo performance. 
Table 4-5: MTD study results of non-tumor bearing nude mice treated with PEG2k-4.1  
Dose (Cisplatin equivalent) Toxic Deaths Time after injection 
8 mg/kg  2/2 4 days 
6 mg/kg 2/2 4 days 
4 mg/kg 2/2 4 days 
  
  
Figure 4-21: Liver histology results of mice treated with saline (A) or PEG2k-4.1 (B) with 
H&E staining at 4x magnification. Purple areas indicate viable cells, pink areas indicate dead 
cells, and red circles indicate red blood cells. Scale bars indicate 0.5 mm. 
4.2.10 Pegylation (MW: 5000) of 4.1 
 As PEG chain length and PEG density can play an important role in optimizing the 
pharmacokinetics and biodistribution of 4.1,29, 31-32 we modified the PEG grafting strategy in 
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order to endow 4.1 with better stealth properties.  Amino-PEG (MW 5000) monomethyl 
ether was synthesized through end group modification of PEG (MW 5000) monomethyl 
ether. Numerous attempts to couple PEG5k-NH2 to 4.1 by EDC mediated couplings were 
unsuccessful, so a HBTU-based coupling in acetonitrile was used to synthesize PEG5k-
4.1(Scheme 4-3). PEG5k-4.1 showed no change in particle morphology by SEM and TEM 
(Figures 4-22 and 4-23); however the hydrodynamic size increased to 150.3 nm (Figure 4-24, 
Table 4-1). This increase in hydrodynamic size was due to a dense layer of conjugated PEG 
chains extending away from the nanoparticle surface. The zeta potential of 4.1 was -6.5 mV 
due to the shielding of the nanoparticle surface charge by the PEG corona. PEG5k-4.1 
contained 22 wt% PEG by TGA (Figure 4-25). This would correspond to a PEG coverage 
density of 1 PEG/ 4.5 nm2, which would allow the PEG to adopt a brush confirmation 
extending away from the nanoparticle surface and provide PEG5k-4.1 with the optimum 
stealth properties.32 
 
Scheme 4-3: Schematic of pegylation of 4.1 to PEG5k-4.1. 
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Figure 4-22: SEM micrographs of PEG5k-4.1. 
 
Figure 4-23: TEM micrographs of PEG5k-4.1. 
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Figure 4-24: Intensity (left) and number (right) weighted DLS spectra of 4.1 (black) and 
PEG5k-4.1 obtained in 5mM PBS.  
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Figure 4-25: TGA weight loss curves for 4.1 (black) and PEG5k-4.1 (green) 
 
4.2.11 Nonspecific Protein Binding and Colloidal Stability in Plasma 
 Nonspecific plasma protein binding to the nanoparticle surface is one of the first steps 
for the MPS system to recognize and thus uptake the nanoparticles, thus playing a major role 
in determining nanoparticle biodistribution.46 A well pegylated nanoparticle should be able to 
resist protein absorption, which would extend systemic circulation. To this end, the colloidal 
stability of 4.1 and PEG5k-4.1 in the presence of bovine serum albumin (BSA), the most 
common type of plasma protein, was investigated. If BSA was bound to the nanoparticle 
surface, the size of the nanoparticles would increase and would also cause them to quickly 
precipitate from the suspension. The sizes of various nanoparticle suspensions (under 
conditions that were shown to be colloidally stable without BSA over the time frame) were 
determined by DLS immediately before adding 500 wt% BSA. Nanoparticle sizes were 
measured every 10 minutes for 3 hours. For unpegylated 4.1, the nanoparticle size 
immediately increased by approximately 100 nm (Figure 4-26) after BSA addition and 
remained relatively constant over the course of the experiment. The instrument count rate, 
which corresponds to the particle concentration of the suspension, gradually decreased over 
145 
 
the course of the experiment, suggesting that the nanoparticles are precipitating from the 
suspension (Figure 4-27). Size distribution data also confirmed the presence of larger, up to 1 
micron, particle agglomerates in solution due to the aggregation (and eventual precipitation) 
of 4.1 with BSA (Figure 4-28). PEG5k-4.1 nanoparticles were also evaluated by this method. 
In contrast to 4.1, the d(Zavg), count rate, and intensity distribution of PEG5k-4.1 remained 
consistent over the experiment (Figures 4-26, 4-27, 4-29) indicating that the PEG layer on the 
nanoparticles prevented nonspecific protein absorption.  Both experimental results are 
reproducible with different nanoparticle batches.  
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Figure 4-26: d(Zavg) trends as a function of exposure to BSA for 4.1 (red) and PEG5k-4.1 
(blue). BSA was added at t =0. 
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Figure 4-27: DLS count rate trends of 4.1 (red) and PEG5k-4.1 (blue) as a function of time 
after exposure to BSA. 
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Figure 4-28: Intensity-weighted DLS curves of 4.1 before (black) and after (blue) BSA 
addition. After curves were obtained every 10 minutes for 3 hours. 
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Figure 4-29: Intensity-weighted DLS curves of PEG5k-4.1 before (black) and after (blue) 
BSA addition. After curves were obtained every 10 minutes for 3 hours. 
Due to some of the biodistribution results obtained in the next sections, the colloidal 
stability in rat plasma was investigated by DLS. PEG5k-4.1was suspended into 1mL 
undiluted rat plasma and DLS measurements were obtained every 10 minutes for 2 hours 
(Figures 4-30 and 4-31) for two different samples of PEG5k-4.1 (PEG5k-4.1(A) and PEG5k-
4.1(B)). In both curves, the smaller peaks (under 50 nm) are due to plasma proteins present in 
solution, so only the larger intensity peaks are indicative of nanoparticle behavior. For 
PEG5k-4.1(A), the intensity size distribution shifted outward to larger hydrodynamic 
diameters, indicating that the nanoparticles are aggregating as a result of plasma protein 
binding (Figure 4.34).  For PEG5k-4.1(B), the particle intensity distribution remained 
relatively unchanged from plasma incubation, indicating a better pegylated nanoparticle 
(Figure 4.35). Both batches of nanoparticles were identical by prior physiochemical 
characterization and could resist BSA binding; however, subtle differences in the PEG 
corona lead to varying degrees of colloidal stability in plasma. This effect was reproducible 
148 
 
within the same batch, but the degree of the control in synthesizing the PEG corona has not 
yet been achieved to reach batch to batch reproducibility.  Future in vivo studies will attempt 
to utilize nanoparticles that are colloidally stable in plasma. It is important to mention that 
this assay was developed in response to the in vivo results obtained in the next sections, so 
some of the studies were performed with batches that were later found to lack stability in 
plasma.  
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Figure 4-31: Colloidal stability measurements of PEG5k-4.1 (A) in rat plasma. 
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Figure 4-31: Colloidal stability of PEG5k-4.1 (B) in rat plasma. 
 
4.2.12 Maximum Tolerated Dose of PEG5k-4.1 
 Before starting efficacy studies, the MTD of PEG5k-4.1 was determined. These 
studies were performed using a batch of nanoparticles that was later found to slightly 
aggregate in plasma and the study was conducted as described in section 4.2.9. PEG5k-4.1 
has a MTD of greater than 20 mg/kg (Table 4-6). These studies are still ongoing, so the true 
MTD of this nanoparticle formulation has not yet been reached.  The mouse weights 
remained relatively consistent, with only slight (<10%) weight loss observed initially. At the 
termination of the study, all dose levels had regained any lost weight (Figure 4-32). The 
MTD of PEG5k-4.1 is at least twice as high as cisplatin44-45 and more than five times higher 
than PEG2k-4.1 (Table 4-5), suggesting that PEG5k-4.1is better tolerated in mice due to the 
improved PEG shell. The liver and spleen of MTD mice receiving 0, 4 mg/kg, 10 mg/kg and 
15 mg/kg doses were also examined by histology (Figures 4-33- 4-36). There were no gross 
morphological changes in the liver as a result of treatment with various doses of PEG5k-4.1 
(Figures 4-33 and 4-34) in contrast to administration of PEG2k-4.1. Spleen morphology 
changes were observed at the 15 mg/kg dose level, indicating that spleen toxicity may play a 
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role in the MTD of PEG5k-4.1; however, further study is needed to determine both the MTD 
and the dose limiting toxicity (Figures 4-35 and 4-36). 
Table 4-6: MTD study results of non-tumor bearing nude mice receiving different dose 
levels of PEG5k-4.1.  
Dose (Cisplatin equivalent) Toxic Deaths 
4mg/kg 0/2 
6mg/kg 0/2 
10mg/kg 0/2 
12mg/kg 0/2 
15 mg/kg 0/2 
20 mg/kg 0/2 
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Figure 4-32: Percent mouse body weight changes after administration of 4 mg/kg (black), 6 
mg/kg (red), 10 mg/kg (green) 12 mg/kg (blue), 15 mg/kg (cyan) or 20 mg /kg (orange) doses 
of PEG5k-4.1 in non-tumor bearing nude mice. All doses are cisplatin equivalent. 
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Figure 4-33: Liver histological images (with H& E staining) obtained at 4 x magnification of 
mice receiving either 0 mg/kg (A), 4 mg/ kg (B), 10 mg/kg (C) or 15 mg /kg (D) doses of 
PEG5k-4.1. All doses are expressed as cisplatin equivalent doses. Scale bars indicate 0.5 
mm. 
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Figure 4-34: Liver histological images (with H& E staining) obtained at 10x magnification 
of mice receiving either 0 mg/kg (A), 4 mg/ kg (B), 10 mg/kg (C) or 15 mg /kg (D) doses of 
PEG5k-4.1. All doses are expressed as cisplatin equivalent doses. Scale bars indicate 500 
µm. 
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Figure 4-35: Spleen histological images (with H& E staining) obtained at 4x magnification 
of mice receiving either 0 mg/kg (A), 4 mg/ kg (B), 10 mg/kg (C) or 15 mg /kg (D) doses of 
PEG5k-4.1. All doses are expressed as cisplatin equivalent doses. Scale bar indicates 0.5 
mm. 
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Figure 4-36: Spleen histological images (with H& E staining) obtained at 10x magnification 
of mice receiving either 0 mg/kg (A), 4 mg/ kg (B), 10 mg/kg (C) or 15 mg /kg (D) doses of 
PEG5k-4.1. All doses are expressed as cisplatin equivalent doses.  Scale bar indicates 500 
µm. 
4.2.13 Biodistribution of PEG5k-4.1 
 The biodistribution of PEG5k-4.1 was investigated in nu/nu mice bearing H460 s.c 
xenografts (Figures 4-37 and 4-38).  Mice were administered PEG5k-4.1(A) i.v. at a 4 mg/kg 
cisplatin dose and were sacrificed 5 minutes, 1 hour, 6 hours and 24 hours post-injection. The 
blood, MPS organs (liver and spleen), kidneys and tumors were harvested. Organs were 
digested in concentrated nitric acid and platinum content was determined by ICP-MS.  
Tumor concentrations of platinum were quite high, reaching a maximum concentration of 14 
µg Pt/g tissue (Figure 4-37, black), which is a much higher concentration than what is 
typically observed for cisplatin (1-2 µg/g).44, 47-48 However, tumor platinum concentrations 
were highly variable presumably due to differences in tumor sizes between individual mice.  
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Clearance of PEG5k-4.1 (A) occurred through the major MPS organs (liver and spleen) with 
the highest platinum concentrations observed in the spleen (Figure 4-37, blue), but the bulk 
of the injected dose accumulating within the liver (Figure 4-38, red). High splenic uptake was 
initially surprising, as the macrophages in the spleen primarily clear larger nanoparticles than 
what was observed for PEG5k-4.1.29 However, considerable aggregation of PEG5k-4.1 (A) 
was observed by DLS in the presence of rat plasma (Figure 4-31), so high splenic 
accumulation was probably due to the aggregation of PEG5k-4.1 (A) in the plasma. PEG5k-
4.1 (A) was also used for the MTD studies above, which also suggested high spleen 
concentrations of platinum. Cisplatin is primarily cleared through the kidneys, resulting in 
dose limiting renal toxicity.49 In contrast, administration of PEG5k-4.1 caused very low renal 
platinum concentrations, typically under 2 µg/g. The circulation properties of PEG5k-4.1 (A) 
appear to have a rapid distribution phase and a slow elimination phase, as there is a rapid 
decline in blood concentration to 1 hour post injection, followed by a slower decline 
afterwards (Figure 4-37, pink; Figure 4-38). There was still a detectable amount of platinum 
present in the bloodstream 24 hours post-injection.   
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Figure 4-37: Platinum concentrations in the tumor (black), liver (red), spleen (blue),  kidneys 
(cyan), and blood (pink) after administration of PEG5k-4.1 (A) to mice bearing H460 s.c. 
xenografts. 
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Figure 4-38: Blood platinum concentration levels over time after administration of PEG5k-
4.1 (A) (red) and PEG5k-4.1 (B) to nu/nu mice. 
 Due to the tendencies of PEG5k-4.1 (A) to aggregate in plasma, the biodistribution 
study was repeated with PEG5k-4.1 (B) (Figures 4-38 and 4-39) PEG5k-4.1 (B) did not 
aggregate in plasma (Figure 4-31).  The blood circulation properties of both batches of 
nanomaterials were similar. PEG5k-4.1 (B) had a higher platinum concentration at 5 minutes 
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post-injection, but are within error of each other after 1 hour (Figure 4-38). It appears that 
plasma aggregation does not have a dramatic effect on the circulation time of PEG5k-4.1. 
However, much less spleen uptake was observed for PEG5k-4.1 (B) at concentrations 
roughly equivalent to hepatic concentrations (Figure 4-39, red and blue). Kidney uptake of 
PEG5k-4.1 (B) remained low.   
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Figure 4-39: Platinum concentrations in liver (red), spleen (blue), kidneys (cyan), and blood 
(pink) after administration of PEG5k-4.1 (B) to mice. 
 The biodistribution profile of PEG5k-4.1 demonstrates some advantages over 
conventional cisplatin administration.  First, PEG5k-4.1 was able to accumulate in the tumor 
region to a much higher extent than normally observed with cisplatin. Nanoparticle 
incorporation also altered the platinum biodistribution profile. Cisplatin demonstrates high 
renal uptake, leading to dose limiting toxicity. PEG5k-4.1 delivered little platinum to the 
kidneys, with the majority being cleared through hepatic pathways. This may present a more 
favorable toxicity profile than cisplatin and alleviate some of its side effects. The circulation 
time of PEG5k-4.1 was fairly short, which may limit its in vivo efficacy. However, we feel 
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that the altered biodistribution and increased MTD of PEG5k-4.1 gives it distinct advantages 
over cisplatin. 
4.2.14 Chemotherapeutic Efficacy of PEG5k-4.1 
 PEG5k-4.1 was also evaluated for its efficacy as a chemotherapeutic against mice 
bearing H460 xenografts (Figure 4-40).  Mice were administered saline control (black), 
cisplatin (4mg/kg, red) or PEG5k-4.1 (4mg cisplatin/kg, blue) via i.v. injection on days 0, 4, 
and 8. Tumor growth was monitored daily and the study concluded when the mice reached 
the maximum allowed size. Mice receiving saline control demonstrated rapid tumor growth, 
reaching the maximum allowed size 15 days after the start of the study.  PEG5k-4.1 both 
demonstrated significant tumor growth inhibition, limiting the tumor size to approximately 
40% of the untreated control mice. Cisplatin was slightly more effective, limiting tumor 
growth to 30% of the untreated control. The two platinum treatment arms were within error 
of each other. Mouse weights remained unchanged as a result of platinum treatment (Figure 
4-41). However, PEG5k-4.1 can be administered at a higher dose than cisplatin, we should be 
able to achieve superior tumor growth inhibition than cisplatin in xenograft models. 
Additional tumor growth inhibition with higher doses of PEG5k-4.1 are being planned in 
order to assess its true chemotherapeutic efficacy. 
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Figure 4-40: Chemotherapeutic efficacy study in mice with H460 s.c. xenografts receiving 
either saline control (black), cisplatin (red, 4mg/kg) or PEG5k-4.1 (blue, 4 mg/kg cisplatin) 
on days 0, 4 and 8.  
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Figure 4-41: Body weight changes in mice with H460 s.c. xenografts receiving either saline 
control (black), cisplatin (red) or PEG5k-4.1 (blue). 
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4.2.15 Lung Cancer Chemoradiotherapy with PEG5k-4.1 
Chemoradiotherapy, the concurrent administration of chemotherapy and radiotherapy, 
has emerged as an additional option to traditional chemotherapy. Chemoradiotherapy is the 
standard of care for many difficult to treat solid cancers, including brain, head and neck, 
esophageal, gastric, pancreatic, lung, rectal, anal, and cervical cancers.6, 50-53 
Chemoradiotherapy has shown consistently improved local tumor control and rates of cancer 
cure compared to either sequential treatment or sole administration of chemotherapy or 
radiotherapy. Chemoradiotherapy is, however, not without limitations; the concurrent use of 
both chemotherapy and radiotherapy has significantly higher toxicities when compared to 
either treatment alone or sequential use. 54-55 The higher toxicity profile of 
chemoradiotherapy limits the administered dose and restricts the patients who are eligible for 
treatment. Furthermore, patients who receive chemoradiotherapy often cannot tolerate further 
treatment, limiting the cure of their disease. Cancer treatment by either chemotherapy or 
chemoradiotherapy can be improved by delivering the chemotherapeutic selectively to the 
tumor region, while minimizing drug exposure to healthy tissue.   
PEG5k-4.1 was evaluated in vivo as a chemoradiotherapy agent. Nanotherapeutics 
have received a lot of attention as chemotherapeutic or imaging contrast agents,56-57 but have 
received scant attention as chemoradiotherapeutics49, 58-62 even though nanotherapeutics 
possess many properties that make them ideally suitable for chemoradiotherapy. PEG5k-4.1 
was evaluated as a chemradiotherapy agent in vivo against mice bearing either A549 (Figure 
4-42) or H460 (Figure 4-43) lung cancer xenografts. Mice received either no treatment, 10 
Gy radiation, cisplatin (1 mg/kg) 6 hours prior to 10 Gy radiation, or PEG5k-4.1 (1 mg 
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cisplatin/kg) 6 hours prior to 10 Gy radiation. For the A549 xenograft (Figure 4-42), all 
treatment groups gave statistically significant tumor growth inhibition compared to the 
untreated control (Table 4-7). Cisplatin did not show any significant effects (α ≤0.05) over 
radiation alone over the course of the study, while PEG5k-4.1 demonstrated a significant (α 
≤0.05) increase in efficacy over radiation alone from day 8 onwards and a significant 
increase over cisplatin at day 22. The endpoint time (5x tumor volume increase for 1 mouse 
in group) was extended from 22 days for radiation only and for cisplatin plus radiation to 30 
days for PEG5k-4.1 plus radiation. For the H460 xenograft (Figure 4-43), all treatment 
groups showed significant tumor growth inhibition compared to the control (Table 4-8). 
Cisplatin demonstrated insignificant chemoradiosensitization effects over the course of the 
study. PEG5k-4.1 demonstrated statistically significant (α ≤0.05) increases in tumor growth 
inhibition over radiation alone over the entire study period and over cisplatin from days 4-8 
and 14-16 (Table 4-8). These results suggest that PEG5k-4.1 is a highly potent 
chemoradiotherapy agent for lung cancer treatment.  
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Figure 4-42: Chemoradiotherapy efficacy assay against mice bearing A549 lung cancer 
xenografts. Mice received either saline control (black), 10 Gy radiation (red), cisplatin 
(1mg/kg) 6 hours prior to 10 Gy radiation (green) or PEG5k-4.1 (1mg cisplatin/kg) 6 hours 
prior to radiation (blue).  
Table 4-7: Comparison of α values of different treatment arms of A549 chemoradiotherapy 
efficacy study by students t-test. 
Comparison Day 6 Day 8 Day 10 Day 12 Day 14 Day 16 Day 18 Day 20 Day 22 
XRT vs 
Control 
0.00331 0.002484        
XRT vs 
Cisplatin 
0.576 0.486 0.190 0.064 0.097 0.094 .080 0.071 0.087 
XRT vs 
PEG5k-4.1 
0.059 0.0036 0.0059 0.015 0.0093 0.0031 0.0025 0.0012 .0010 
Cisplatin vs 
PEG5k-4.1 
0.353 0.2235 0.315 0.491 0.302 0.116 0.077 0.055 0.0471 
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Figure 4-43: Chemoradiotherapy efficacy assay against mice bearing H460 lung cancer 
xenografts. Mice received either saline control (black), 10 Gy radiation (red), cisplatin 
(1mg/kg) 6 hours prior to 10 Gy radiation (green) or PEG5k-4.1 (1mg cisplatin/kg) 6 hours 
prior to radiation (blue). 
Table 4-8: Comparison of α values of different treatment arms of H460 chemoradiotherapy 
efficacy study by students t-test. 
Comparison Day 4 Day 6 Day 8 Day 10 Day 12 Day 14 Day 16 
XRT vs 
Control 
0.064 0.052 0.059 0.060    
XRT vs 
Cisplatin 
0.519 0.437 0.113 0.039 0.189 0.336 0.419 
XRT vs 
PEG5k-4.1 
0.0052 0. 0015 0.0024 0.0060 0.0165 0.0194 0.0161 
PEG5k-4.1 
vs cisplatin  
0.0165 0.0051 0.0119 0.0784 0.0630 0.0419 0.0210 
 
4.3 Conclusions 
 A new type of polysilsesquioxane nanoparticle containing cisplatin, 4.1, was 
synthesized. As-synthesized 4.1 was 64 nm in diameter by electron microscopy, but showed 
hydrogel-like behavior in aqueous solution, swelling to 134 nm in diameter under 
physiological conditions. 4.1 had an exceptionally high drug loading of 42 wt% cisplatin and 
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drug release can be triggered by endogenous reducing agents. Abundant surface carboxylic 
acid groups on 4.1 allowed for the post-synthetic modification with cancer targeting peptides 
(cRGD) or passivating polymers (PEG). In vitro efficacy of 4.1 and RGD-4.1 was evaluated 
against 3 different cancer cell lines. 4.1 possessed comparable cytotoxicity as cisplatin 
against all three cell lines, with RGD targeting providing an increase in efficacy in αvβ3 
overexpressing cell lines.   
PEG chains of varying lengths (MW= 2000 or 5000) could be conjugated to 4.1 
through amide coupling reaction and a targeted, pegylated nanoparticle could be synthesized 
by adding a fraction of anisamide PEG2k to the pegylation reaction. PEG2k-4.1 and 
APEG2k-4.1 demonstrated comparable in vitro efficacy as cisplatin, with APEG2k-4.1 
increasing efficacy in the sigma-receptor over-expressing H460 cell line.  Initial in vivo 
evaluations of PEG2k-4.1 and PEG5k-4.1 were performed in a lung cancer xenograft model.  
All platinum treatment modalities demonstrated nearly identical tumor growth inhibition. Ex 
vivo tumor histology demonstrated that the nanoparticle treatment groups were highly 
effective, creating large regions of necrotic tissue in the center of the tumor. However, mice 
in all three platinum treatment arms showed toxicity-related death, so the treatments might 
have been too aggressive.  The MTD of PEG2k-4.1 was less than 4mg/kg, a value well below 
that of cisplatin and PEG2k-4.1 was revealed to cause a significant amount of liver damage 
by histology.  
PEG5k-4.1 was developed to improve the in vivo performance of 4.1. PEG5k-4.1 was 
much better tolerated in mice with a MTD of at least 20 mg/kg. Liver toxicity was greatly 
diminished in PEG5k-4.1 with splenic damage observed at the highest doses.  Biodistribution 
studies revealed that PEG5k-4.1 had very high tumor uptake, approximately 10 times what is 
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typically observed with cisplatin. Renal platinum uptake was greatly diminished, with 
PEG5k-4.1 primarily removed by the liver and the spleen. PEG5k-4.1 was evaluated as a 
chemotherapy and chemoradiotherapy agent in vivo. As a chemotherapy agent, PEG5k-4.1 
demonstrated similar tumor growth inhibition as cisplatin; but future studies can utilize the 
fact that PEG5k-4.1 can be administered at a higher dose than cisplatin to achieve superior 
tumor growth inhibition. PEG5k-4.1 was evaluated as a chemoradiotherapy agent in two lung 
cancer xenograft models. The nanoparticles had statistically significant radiosensitization 
effects, while cisplatin provided no statistically significant effects. Nanoparticles 4.1 show 
considerable promise in the treatment of lung cancer by various modalities, but more 
systemic in vivo evaluations must be performed to elucidate the clinical potential of this 
novel nanotherapeutic.  
4.4 Materials and Methods 
4.4.1 General Materials and Methods 
All chemicals were purchased from Fisher or Aldrich and used without further purification 
unless noted.  Cisplatin was purchased from AK scientific. Tetrahydrofuran was dried by the 
sodium metal/benzophenone method.  Dimethylformamide was dried by activated alumina. 
Thermogravimetric analysis was performed using a Shimadzu TGA-50 equipped with a 
platinum pan and heated at 3°C per minute in air. A JEM 100CX-2 transmission electron 
microscope (TEM) and a Hitachi S-4700 scanning electron microscope (SEM) were used to 
determine particle size and morphology. TEM and SEM samples were prepared from 
ethanolic suspensions of the nanoparticles dropped onto amorphous carbon coated copper 
grids. The solvent was then allowed to evaporate. Dynamic light scattering (DLS) and zeta 
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potential measurements were made using a Malvern Instruments Zetasizer Nano.  
Inductively-Coupled Plasma Mass Spectrometry (ICP-MS) measurements were made using a 
Varian 820-MS Inductively-Coupled Plasma Mass Spectrometer. ICP-MS samples were 
prepared by digesting a known amount of sample in concentrated nitric acid overnight, and 
then diluted with water to 2% nitric acid by volume.  
4.4.2 Synthesis of Platinum Compounds 
Synthesis of all platinum compounds was as previously described in chapter 3 of this 
dissertation. 
4.4.3 Synthesis of Polyethylene Glycol (PEG) derivatives 
Synthesis of amino-polyethylene glycol (MW= 2000) monomethyl ether 
Methoxy-PEG2000-amine was synthesized as described in Chapter 2. 
Synthesis of anisamide-PEG2000-NH2 
 Anisamide-PEG2000-NH2 was synthesized as described in Chapter 2. 
Synthesis of amino-polyethylene glycol (MW= 5000) monomethyl ether 
Amino-Polyethylenegylcol (MW=5000) monomethyl ether was synthesized through a 
modification of an established protocol.33   Polyethylene glycol (MW=5000) 
monomethylether (30g) was dried under vacuum at 90°C overnight to remove moisture. 
Anhydrous tetrahydrofuran (360 mL) was added with 3.6 mL (46.5 mmol) of 
methanesulfonyl chloride. The solution was cooled to 0°C on an ice bath and 6.9 mL 
tryethylamine dissolved in 60mL THF was added dropwise. The resulting solution was 
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stirred under nitrogen from 0°C to room temperature overnight.  Water (150 mL) was added 
and the solution was cooled back to 0°. A sodium bicarbonate solution (1M, 15mL) and 
sodium azide (3.9g, 60mmol) were added. The THF was removed by rotary evaporation and 
the remaining aqueous solution was refluxed for 24 hours. PEG-azide was extracted with 
dichloromethane (4x100 mL). The organic layers were collected, concentrated, and extracted 
with brine. The organic solution was then dried with magnesium sulfate, filtered and then the 
dichloromethane was removed by rotary evaporation. (21.2g, 70% yield) 1H NMR (CDCl3) δ 
2.93(2H), 3.33 (3H), 3.42 (3H), 3.50 (4H), 3.53-3.75(410H), 3.77 (4H).    The monomethyl 
PEG-azide complex (6.083g) was heated to 80°C before being dissolved into 115mL THF 
and triphenylphosphine (3.174 g, 12.1mmol) was added. The solution was stirred at room 
temperature for 12 hours. Water (9.1mL) was then added and the solution was stirred for 18 
hours. The THF solvent was removed by rotary evaporation and the residue was redissolved 
in water (150mL), precipitating triphenylphosphine oxide.  The triphenylphosphine 
byproducts were removed by filtration and the water removed by rotary evaporation.  (3.95g, 
65% yield).  
4.4.4 Nanoparticle 4.1 Synthesis 
Sixty milligrams of DSCPSi (6.36X10-5 mol) were dissolved into 3 mL 33% ammonium 
hydroxide, 4.5 mL water and 6 mL of ethanol.  The yellow solution was stirred vigorously at 
room temperature for 1 hour, yielding a bluish white suspension. The suspension was loaded 
onto an amberlite IRC-50 cation exchange column and the nanoparticles were eluted using 
water. The nanoparticle containing fractions were loaded into a 3500 MW cutoff dialysis bag 
and dialyzed against 500mL water for 3 hours, changing water hourly.   4.1 was concentrated 
by centrifugation, washed with ethanol once and stored as an ethanolic suspension. 
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4.4.5 Platinum Release Assays 
Four hundred milliliters of 2mM HEPES buffer (pH=7.4) was placed in a 2-neck round 
bottom flask, sparged with nitrogen gas and prewarmed to 37 °C.  Two milligrams of 4.1 
(1.84 µmol Pt) was suspended into 2mL of the buffer solution. The nanoparticle suspension 
was then added to the large buffer sink and the system was incubated at 37°C under N2 
blanket.  Periodically, 1.2mL aliquots of the solution were removed. After 1 day of 
incubation, a solution of L-cysteine in 2mM HEPES buffer was added to make the total 
reducing agent concentration either 5mM or 15 µM. The resulting system was incubated at 
37°C, with 1.2 mL aliquots periodically removed.  The removed aliquots were processed by 
filtering the suspensions through a Costar Spin-X centrifuge tube filter (0.22 µm cellulose 
acetate).  The filtrate was collected and analyzed by ICP-MS. 
4.4.6 Nanoparticle Surface Modification 
Conjugation of cRGDfK to 4.1 (RGD-4.1): The cRGDfK peptide was conjugated to the 
surface of 4.1 through surface carboxylate groups. Briefly, 3 mg of 4.1 was redispersed into 2 
mL of a freshly prepared solution of 25 mM EDC and 25 mM NHS (EDC=  1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, NHS= N-hydroxysuccinimide). The suspension was 
heated at 50°C for 2 hours to form the NHS ester, then the suspension was cooled to room 
temperature. cRGDfK (0.5 mg, 0.8 µmol) was then added to the suspension and the 
suspension was stirred overnight at room temperature to form RGD-4.1. RGD-4.1 was 
isolated by centrifugation and washed with water 1x and ethanol 2x. RGD-4.1 was stored as 
an ethanolic suspension. 
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Conjugation of PEG (MW: 2000) amine to 4.1 (PEG2k-4.1): Nine milligrams of 4.1 were 
redispersed into 4mL of DMF (2.25 mg/mL). EDC (36 mg, 1.87x10-4 mol) and amino-
poly(ethylene)glycol monomethyl ether (MW=2000)(86 mg, 4.3x10-5 mol) were dissolved 
into the suspension. The suspension was vigorously stirred, covered, at room temperature 
overnight. An equal volume of ethanol was added to dilute the suspension and PEG2k-4.1 
was isolated by centrifugation. PEG2k-4.1 was washed with ethanol 3x and stored as an 
ethanolic suspension. 
Conjugation of Anisamide-PEG (MW: 2000) to 4.1 (APEG2k-4.1): Anisamide-targeted 4.1 
(APEG2k-4.1) was synthesized by the same procedure as PEG2k-4.1, except that a fraction, 
typically 10 wt% of anisamide-PEG2000-NH2 was added to the PEG feed.  
Conjugation of PEG (MW: 5000) amine to 4.1 (PEG5k-4.1): 4.1 was pegylated through the 
surface carboxylic acids. 4.1 (15mg) was suspended into acetonitrile (15 mL). To the 4.1 
suspension, aminopolyethylene glycol monomethyl ether (MW=5000, 75mg), triethylamine 
(37.5 µL) and HBTU (45mg) were added. The suspension was stirred at room temperature 
for 24 hours before the nanoparticles were isolated by centrifugation and washed with 
acetonitrile twice and ethanol once. PEG5k-4.1 was stored as an ethanolic suspension.   
4.4.7 Colloidal Stability in Biological Media 
Bovine Serum Albumin nonspecific binding: In order to determine the ability of the 
synthesized nanoparticles to resist plasma protein absorption, we performed colloidal 
stability tests in the presence of BSA. Various forms of 4.1 were dispersed into a 5mM PBS 
solution at 0.5 mg NP/mL. The nanoparticle size was measured by dynamic light scattering. 
BSA (2.5 mg, 5x weight) was then dissolved into the nanoparticle suspension. DLS 
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measurements were obtained every 10 minutes for 3 hours to size the suspension. Differences 
in the Zavg and count rate of the solution were used to determine extent of protein binding and 
sedimentation.   
Rat Plasma stability: Colloidal stability in rat plasma was also determined by DLS. Various 
forms of 4.1 (0.45 mg) were dispersed into 1mL rat plasma (Innovative Research, Novi, MI). 
DLS measurements were taken every 10 minutes for 2 hours. Changes in intensity weighted 
size distributions and count rate were used to determine the colloidal stability.   
4.4.8 In vitro assays 
General: NCI-H460 human large cell lung carcinoma (ATCC# HTB-177), A549 human lung 
carcinoma cells (ATCC# CCL-185) and PC-3 human prostate adenocarcinoma  cells 
(ATCC# CRL-1435) were all purchased from the Tissue Culture Facility of the Lineberger 
Comprehensive Cancer Center. All cells were maintained at 37°C with 5% CO2. Cisplatin 
was purchased from AK Scientific and stored in PBS. All nanoparticle suspensions were 
freshly made from sterile PBS. NCI-H460 cells were cultured in RPMI-1640 medium 
(Gibco) supplemented with 10% FBS (Mediatech) and 2% Penicillin- Steptomycin solution 
(Mediatech).  PC-3 cells were cultured in Ham’s F-12 media (Gibco) supplemented with 
10% FBS (Mediatech) and 2% Penicillin- Streptomycin solution (Mediatech).  A549 cells 
were cultured in MEM (Gibco) supplemented with 10% FBS (Mediatech) and 2% Penicillin- 
Streptomycin solution (Mediatech) 
Cell Viability Assay: NCI-H460 cells: NCI-H460 cells were plated in 6 well plates at a 
concentration of 300,000 cells/well and incubated in 3 mL media for 12 hours to promote cell 
attachment.  The plates were then washed once with 2mL PBS and subsequently given 2 mL 
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media containing varying drug concentrations. The plates were incubated at 37°C for 48 
hours and cell viability was determined by the trypan blue dye exclusion method. 
Cell Viability Assay: A549 Cells: Confluent A549 cells were trypsinized and counted via a 
hematocytometer. Cells were plated into 6-well plates at a cell density of 1.0 x 105 cells/well 
and 3 mL total volume (RPMI-1640 complete growth medium). The cells were incubated 
overnight at 37°C and 5% CO2. Media was removed from the wells and aliquots of free drug 
(or particles) and media (5% phosphate buffered saline, PBS) were added to each well to 
ensure final drug concentrations of 0, 0.25, 0.5, 1, 2.5, and 5 µM. The plates were incubated 
(37°C, 5% CO2) for 72 hours with a media switch being done on the second day. Each well 
was washed with 2 mL PBS, trypsinized, and cell viability determined by the trypan blue 
exclusion assay. 
Confluent A549 cells were trypsinized and counted via a hematocytometer. Cells were plated 
into 6-well plates at a cell density of 1.0 x 105 cells/well and 3 mL total volume (RPMI-1640 
complete growth medium). The cells were incubated overnight at 37°C and 5% CO2. Media 
was removed from the wells and aliquots of free drug (or particles) and media (5% phosphate 
buffered saline, PBS) were added to each well. The plates were incubated (37°C, 5% CO2) 
for three days. Each well was washed with 2 mL PBS, trypsinized, and cell viability 
determined by the trypan blue exclusion assay. 
Cell Viability Assay: PC-3 Cells: PC-3 cells were plated in 6 well plates at a concentration of 
300,000 cells/well  and incubated in 3 mL media for 12 hours to promote cell attachment.  
The plates were then washed once with 2mL PBS and subsequently given 2 mL media 
172 
 
containing varying drug concentrations. The plates were incubated at 37°C for 48 hours and 
cell viability was determined by the trypan blue dye exclusion method. 
4.4.9: In vivo assays 
General: Mice (male nu/nu, 4-6 weeks old) were purchased from the animal colony at the 
UNC Lineberger cancer center unless noted.  Mice were housed in an AALAC accredited 
facility in sterile housing at UNC Chapel Hill. All animal work was approved and monitored 
by The University of North Carolina at Chapel Hill Animal Care and Use Committee.  
Maximum Tolerated Dose: Maximum tolerated dose (MTD), defined as the highest possible 
dose resulting in no animal deaths and less than 20% weight loss was evaluated for PEG2k-
4.1 and PEG5k-4.1.  Non-tumor bearing mice (nu/nu) were injected with varying amounts of 
PEG-cis-PSQ in PBS by tail vein injection. The mice were weighed and observed daily for 
any change in physical activity. Weight loss greater than 20% and/or lethargy were 
interpreted as signs of toxicity and the mice were euthanized immediately.  
Biodistribution Studies-H460 Tumor Bearing Mice: NCI-460 cells were inoculated in the 
right flank of nu/nu mice at 500,000 cells/ mouse (200 µL of cell media). Tumors were 
allowed to grow until each was between 100-200 mg. PEG5k-4.1 was injected at 4mg 
cisplatin/kg (80µL saline) via the tail vein.  Mice were euthanized 5 minutes, 1 hour, and 24 
hours post-injection (2-3 mice per time point).  The tumor, liver, spleen, intestines, lungs, 
kidney, and heart were removed. All organs were flash-frozen and stored at -20°C. Blood 
was removed by cardiac puncture prior to euthanasia and stored in EDTA-treated tubes. All 
blood samples were stored at 4°C prior to analysis.  Tissues were weighed prior to digestion 
in concentrated nitric acid overnight.  Digestate ( 150 µL) was placed in a vial and diluted to 
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4mL total volume with water. The solution was then filtered used a 0.45 µm PTFE filter to 
remove undissolved species. Platinum concentrations was determined by ICP-MS.  
Biodistribution Studies-non-Tumor Bearing Mice: Studies were performed as above, except 
with non-tumor bearing nu/nu mice.  
In vivo efficacy: H460 Xenograft Study 1: Athymic nude mice were purchased from Jackson 
Laboratories. Mice were cared for according to an approved protocol by the institutional 
animal care and use committee at the University of North Carolina.  H460 cells were 
suspended in a 50% matrigel (BD Biosciences) and 50% RPMI-1640 media at 5 million 
cells/mL. Mice were injected subcutaneosusly in the right flank with 200 µL of the cell 
suspension (1 million cells). Tumor growth was measured daily and treatment commenced 
when tumors were measurable in each flank.  Mice were divided randomly into 4 groups (4-5 
mice/group) and received either control (PBS), cisplatin (4mg/kg), Peg2k-4.1 (4mg 
cisplatin/kg), or APEG2k-4.1 (4mg cisplatin/kg). All injections were administered through 
the tail vein with 100 µL total injection volume. Mice received treatments on days 0, 2, and 
4. Tumor growth was measured daily until the mice reached the maximum allowed tumor 
size.  Tumor volume was calculated by the formula (axbxc)/2, where a, b, and c are the three 
tumor dimensions.  Mice weights were recorded weekly. The mice were euthanized by CO2 
inhalation followed by cervical dislocation and the tumors were removed and stored in 
formalin.  
In vivo efficacy: H460 Xenograft Study 2: Anthymic nude mice (male 4-6 weeks old) were 
obtained from the Lineberger Cancer Center colony. All animal care was done in accordance 
with an approved protocol by UNC Institutional Animal Care and Use Committee. NCI-
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H460 cells (5 million cells) were suspended in a 1:1 media:matrigel mixture and implanted 
subcutaneously in the right flank of each mouse (200 µL total volume). Tumor size was 
measured daily and the study commenced when tumors were palpable (2-4 days after tumor 
implantation). Mice were divided randomly into 3groups (9 mice per group) and received 
either saline control, cisplatin (4mg/kg), or PEG5k-4.1 (4mg cisplatin/kg). All injections 
were performed on days 0, 4, and 8 through the tail vein (100 µL) total volume. Tumors were 
measured daily until the mice reached the maximum allowed tumor size. Tumor volume was 
calculated by the formula (axbxc)/2, where a, b, and c are the three tumor dimensions.  Mice 
weights were recorded weekly. The mice were euthanized by CO2 inhalation followed by 
cervical dislocation. The tumors were removed and stored in formalin.  
In vivo efficacy: Chemoradiotherapy: A549 or H460 cells (1x106 cells in 200 μL 1:1RPMI-
1640 and matrigel) were subcutaneously in the upper dorsal region of 6-8 week-old Nu/Nu 
mice. Twelve days after inoculation, the mice were randomly distributed into different 
groups for subsequent treatment (NP cisplatin, free cisplatin, XRT Only, and control). NP 
cisplatin or free cisplatin in water was tail vein i.v. injected at a dose of 1mg/Kg. Six hours 
post injection, the tumors were subjected to a dose of 10 Gy with XRAD 320. Mice were 
shielded with a lead shield allowing radiation of the tumor site and minimal radiation to other 
organs. Tumor volumes were calculated by measuring two perpendicular diameters with a 
caliper and using the formula of V=0.5 x a x b2, where ‘a’ and ‘b’ are the larger and smaller 
diameters, respectively. The tumor volumes are measured every 2 days, and the relative 
percent change in tumor volume was calculated using the relation 100* (Vi-Vo)/Vo, where Vi 
is the volume calculated and Vo is the initial volume on day 1. 
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Tissue Histology: All evaluated organs were received in a neutral buffered formalin (10%) 
solution. Organs were placed in labeled cassettes and flushed with water for 20 minutes. The 
cassettes were stored in a 70% ethanol solution and were processed (placed in paraffin, 
sectioned, H&E stained, and mounted) at the UNC Lineberger Cancer Center Animal 
Histopathology Core Laboratory. Stained organs were images at the UNC Microscopy 
Services Laboratory using an Olympus BX61 Upright Fluorescence Microscope equipped 
with Improvision’s Volocity software. Images were captured using a QImaging RETIGA 
4000R color camera.  
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